Note 1. Basis of presentation and summary of significant accounting policies
\n\u00a0
\nThe accompanying unaudited\u00a0interim consolidated financial statements reflect the accounts of the Company for the quarterly period ended February 28, 2026\u00a0(the \u201cFinancial Statements\u201d). The Financial Statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (\u201cSEC\u201d) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the \u201cAnnual Financial Statements\u201d) included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\u00a0 May 31, 2025\u00a0(the \u201cAnnual Report\u201d). These\u00a0Financial Statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for the\u00a0full fiscal year.\u00a0
\n\u00a0
\nThe\u00a0Financial Statements have been prepared on a\u00a0going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company\u2019s accounting policies.
\n\u00a0
\nAll amounts in the Financial Statements, and the accompanying notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.
\n\u00a0
\n\n
Basis of consolidation
\u00a0
Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\u00a0
\n \n\n
Restricted cash
\u00a0
We classify cash that is\u00a0legally or contractually restricted as to withdrawal or usage\u00a0as restricted cash.\u00a0As of\u00a0 February\u00a028,\u00a02026, the Company reported $44,885\u00a0of restricted cash related to\u00a0the funds held in escrow in connection with\u00a0the\u00a0acquisition of BrewDog plc (\u201cBrewDog\u201d), which was completed on March 2, 2026. See Note 26\u00a0(Subsequent Events).
\u00a0
\n \n\n
Reverse stock split
\u00a0
Effective December 2, 2025, the Company implemented a reverse stock split of its outstanding shares of Common Stock, at a ratio of one-for-\u00a0(the \u201cReverse Stock Split\u201d).\u00a0
\u00a0
No fractional shares were issued in connection with the Reverse Stock Split. Fractional shares resulting from the Reverse Stock Split were rounded down to the nearest whole share and stockholders\u00a0received cash in lieu of any fractional shares that were created by the Reverse Stock Split.\u00a0Each stockholder's percentage ownership interest in the Company and proportional voting power\u00a0remained unchanged as a result of the Reverse Stock Split, except for adjustments that\u00a0resulted from rounding fractional shares down to whole shares.
\u00a0
All issued and outstanding Common Stock, per share amounts, and outstanding equity instruments and awards exercisable into Common Stock contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Reverse Stock Split\u00a0for all prior periods presented.
\u00a0
\n \n\n
Earnings (loss) per share
\u00a0
Basic earnings (loss) per share is computed by dividing reported net loss\u00a0attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net loss\u00a0attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a012\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\u00a0
In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss attributable to Tilray shareholders is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three months\u00a0ended\u00a0 February 28, 2026 and\u00a0 February 28, 2025, the dilutive potential common share equivalents outstanding consisted of the following: 7,626,712 and 2,189,612 common shares from RSUs, 303,199 and 303,256 common shares from share options, and 620,900 common shares for warrants and 3,766,478\u00a0and 4,873,823 common shares for convertible debentures, respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025.\u00a0
\u00a0
\n \n\n
Digital Assets
\u00a0
In December 2023, FASB issued ASU\u00a02023-08,\u00a0Intangibles\u2014Goodwill and Other\u2014Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of\u00a0income (loss) and comprehensive income (loss) each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis, fair value, and number of units for each significant crypto asset holding.\u00a0In conjunction with the acquisition of digital assets during the fiscal quarter ended August 31, 2025, the Company adopted and applied ASU-2023-08 henceforth.\u00a0
\u00a0
The Company's digital assets are initially recorded at cost, and are subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance with ASC 820,\u00a0Fair Value Measurement, based on quoted prices in\u00a0its principal market for Bitcoin (Level 1). Changes in fair value are recognized as incurred in the Company's consolidated statement of income (loss) and comprehensive income (loss), as \u201cUnrealized (gain) loss on digital assets,\u201d within\u00a0non-operating (income) and expenses, net.\u00a0
\u00a0
\n \n\n
New accounting pronouncements\u00a0not\u00a0yet adopted
\u00a0
In\u00a0 August 2023,\u00a0the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\u201cASU\u201d)\u00a02023-05,\u00a0Business Combination - Joint Venture Formations\u00a0(Subtopic\u00a0805-60) Recognition and Initial Measurement (\u201cASU\u00a02023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU\u00a02023-05\u00a0is effective for the Company beginning\u00a0 June 1, 2026.\u00a0This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.
\u00a0
In October\u00a02023,\u00a0the FASB issued ASU\u00a02023-06,\u00a0Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X\u00a0or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027,\u00a0the SEC has\u00a0not\u00a0removed the applicable requirement from Regulation S-X\u00a0or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will\u00a0not\u00a0become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\u00a0
In December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company beginning with its\u00a0fiscal year ended\u00a0 May 31, 2026\u00a0and will be disclosed\u00a0in the Financial\u00a0Statements reported in our Annual Report on Form\u00a010-K filed with the SEC for such period.\u00a0The Company is in the process of evaluating the impact of the financial statement disclosure requirement.
\u00a0
In November 2024,\u00a0the FASB issued ASU\u00a02024-03,\u00a0Income Statement\u2014Reporting Comprehensive Income\u2014Expense Disaggregation Disclosures (Subtopic\u00a0220-40): Disaggregation of Income Statement Expenses,\u00a0which requires disaggregated disclosure of income statement expenses for public business entities. ASU\u00a02024-03\u00a0is effective for the Company beginning fiscal year ended\u00a0 May 31, 2028\u00a0and will be disclosed\u00a0in the Annual Report on Form\u00a010-K for such period.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\u00a0
New accounting pronouncements recently adopted
\u00a0
In\u00a0 November 2024,\u00a0the FASB issued ASU\u00a02024-04,\u00a0Debt with Conversion and Other Options (Subtopic\u00a0470-20): Induced Conversions of Convertible Debt Instruments,\u00a0which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The Company adopted ASU\u00a02024-04\u00a0beginning\u00a0 June 1, 2025,\u00a0however, it\u00a0did\u00a0not\u00a0have any impact on our unaudited\u00a0interim consolidated financial statements.
\u00a0
\n \n \n \n "}]},{"name":"rpt:f-835","factDimensions":{"xbrl:concept":"us-gaap:ConsolidationPolicyTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Basis of consolidation
\u00a0
Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\u00a0
"}]},{"name":"rpt:f-836","factDimensions":{"xbrl:concept":"us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Restricted cash
\u00a0
We classify cash that is\u00a0legally or contractually restricted as to withdrawal or usage\u00a0as restricted cash.\u00a0As of\u00a0 February\u00a028,\u00a02026, the Company reported $44,885\u00a0of restricted cash related to\u00a0the funds held in escrow in connection with\u00a0the\u00a0acquisition of BrewDog plc (\u201cBrewDog\u201d), which was completed on March 2, 2026. See Note 26\u00a0(Subsequent Events).
\u00a0
"}]},{"name":"rpt:f-837","factDimensions":{"xbrl:concept":"us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"44885000","decimals":-3}]},{"name":"rpt:f-838","factDimensions":{"xbrl:concept":"tlry:ReverseStockSplitPolicyTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Reverse stock split
\u00a0
Effective December 2, 2025, the Company implemented a reverse stock split of its outstanding shares of Common Stock, at a ratio of one-for-\u00a0(the \u201cReverse Stock Split\u201d).\u00a0
\u00a0
No fractional shares were issued in connection with the Reverse Stock Split. Fractional shares resulting from the Reverse Stock Split were rounded down to the nearest whole share and stockholders\u00a0received cash in lieu of any fractional shares that were created by the Reverse Stock Split.\u00a0Each stockholder's percentage ownership interest in the Company and proportional voting power\u00a0remained unchanged as a result of the Reverse Stock Split, except for adjustments that\u00a0resulted from rounding fractional shares down to whole shares.
\u00a0
All issued and outstanding Common Stock, per share amounts, and outstanding equity instruments and awards exercisable into Common Stock contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Reverse Stock Split\u00a0for all prior periods presented.
\u00a0
"}]},{"name":"rpt:f-839","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Earnings (loss) per share
\u00a0
Basic earnings (loss) per share is computed by dividing reported net loss\u00a0attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net loss\u00a0attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a012\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\u00a0
In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss attributable to Tilray shareholders is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three months\u00a0ended\u00a0 February 28, 2026 and\u00a0 February 28, 2025, the dilutive potential common share equivalents outstanding consisted of the following: 7,626,712 and 2,189,612 common shares from RSUs, 303,199 and 303,256 common shares from share options, and 620,900 common shares for warrants and 3,766,478\u00a0and 4,873,823 common shares for convertible debentures, respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025.\u00a0
\u00a0
"}]},{"name":"rpt:f-840","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"7626712"}]},{"name":"rpt:f-841","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"2189612"}]},{"name":"rpt:f-842","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"303199"}]},{"name":"rpt:f-843","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"303256"}]},{"name":"rpt:f-844","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:WarrantsMember"},"factValues":[{"value":"620900"}]},{"name":"rpt:f-845","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"3766478"}]},{"name":"rpt:f-846","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"4873823"}]},{"name":"rpt:f-847","factDimensions":{"xbrl:concept":"tlry:DigitalAssetsPolicyTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Digital Assets
\u00a0
In December 2023, FASB issued ASU\u00a02023-08,\u00a0Intangibles\u2014Goodwill and Other\u2014Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. ASU 2023-08 requires certain crypto assets to be measured at fair value separately on the balance sheet with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of\u00a0income (loss) and comprehensive income (loss) each reporting period. ASU 2023-08 also enhances the other intangible asset disclosure requirements by requiring the name, cost basis, fair value, and number of units for each significant crypto asset holding.\u00a0In conjunction with the acquisition of digital assets during the fiscal quarter ended August 31, 2025, the Company adopted and applied ASU-2023-08 henceforth.\u00a0
\u00a0
The Company's digital assets are initially recorded at cost, and are subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance with ASC 820,\u00a0Fair Value Measurement, based on quoted prices in\u00a0its principal market for Bitcoin (Level 1). Changes in fair value are recognized as incurred in the Company's consolidated statement of income (loss) and comprehensive income (loss), as \u201cUnrealized (gain) loss on digital assets,\u201d within\u00a0non-operating (income) and expenses, net.\u00a0
\u00a0
"}]},{"name":"rpt:f-848","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"New accounting pronouncements\u00a0not\u00a0yet adopted
\u00a0
In\u00a0 August 2023,\u00a0the Financial Accounting Standards Board (\u201cFASB\u201d) issued Accounting Standards Update (\u201cASU\u201d)\u00a02023-05,\u00a0Business Combination - Joint Venture Formations\u00a0(Subtopic\u00a0805-60) Recognition and Initial Measurement (\u201cASU\u00a02023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU\u00a02023-05\u00a0is effective for the Company beginning\u00a0 June 1, 2026.\u00a0This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.
\u00a0
In October\u00a02023,\u00a0the FASB issued ASU\u00a02023-06,\u00a0Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X\u00a0or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027,\u00a0the SEC has\u00a0not\u00a0removed the applicable requirement from Regulation S-X\u00a0or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will\u00a0not\u00a0become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\u00a0
In December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company beginning with its\u00a0fiscal year ended\u00a0 May 31, 2026\u00a0and will be disclosed\u00a0in the Financial\u00a0Statements reported in our Annual Report on Form\u00a010-K filed with the SEC for such period.\u00a0The Company is in the process of evaluating the impact of the financial statement disclosure requirement.
\u00a0
In November 2024,\u00a0the FASB issued ASU\u00a02024-03,\u00a0Income Statement\u2014Reporting Comprehensive Income\u2014Expense Disaggregation Disclosures (Subtopic\u00a0220-40): Disaggregation of Income Statement Expenses,\u00a0which requires disaggregated disclosure of income statement expenses for public business entities. ASU\u00a02024-03\u00a0is effective for the Company beginning fiscal year ended\u00a0 May 31, 2028\u00a0and will be disclosed\u00a0in the Annual Report on Form\u00a010-K for such period.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\u00a0
New accounting pronouncements recently adopted
\u00a0
In\u00a0 November 2024,\u00a0the FASB issued ASU\u00a02024-04,\u00a0Debt with Conversion and Other Options (Subtopic\u00a0470-20): Induced Conversions of Convertible Debt Instruments,\u00a0which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The Company adopted ASU\u00a02024-04\u00a0beginning\u00a0 June 1, 2025,\u00a0however, it\u00a0did\u00a0not\u00a0have any impact on our unaudited\u00a0interim consolidated financial statements.
\u00a0
"}]},{"name":"rpt:f-849","factDimensions":{"xbrl:concept":"us-gaap:InventoryDisclosureTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 2. Inventory
\n\u00a0
\nInventory consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Beverage inventory | \u00a0 | $ | 67,424 | \u00a0 | \u00a0 | $ | 63,965 | \u00a0 |
| Cannabis plants | \u00a0 | \u00a0 | 30,872 | \u00a0 | \u00a0 | \u00a0 | 24,045 | \u00a0 |
| Dried cannabis | \u00a0 | \u00a0 | 110,315 | \u00a0 | \u00a0 | \u00a0 | 103,507 | \u00a0 |
| Cannabis derivatives | \u00a0 | \u00a0 | 4,227 | \u00a0 | \u00a0 | \u00a0 | 7,877 | \u00a0 |
| Cannabis vapes | \u00a0 | \u00a0 | 1,747 | \u00a0 | \u00a0 | \u00a0 | 1,860 | \u00a0 |
| Packaging and other inventory items | \u00a0 | \u00a0 | 13,746 | \u00a0 | \u00a0 | \u00a0 | 15,366 | \u00a0 |
| Distribution inventory | \u00a0 | \u00a0 | 49,901 | \u00a0 | \u00a0 | \u00a0 | 38,735 | \u00a0 |
| Wellness inventory | \u00a0 | \u00a0 | 14,071 | \u00a0 | \u00a0 | \u00a0 | 15,527 | \u00a0 |
| Total | \u00a0 | $ | 292,303 | \u00a0 | \u00a0 | $ | 270,882 | \u00a0 |
\u00a0\u00a0
\n "}]},{"name":"rpt:f-850","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Beverage inventory | \u00a0 | $ | 67,424 | \u00a0 | \u00a0 | $ | 63,965 | \u00a0 |
| Cannabis plants | \u00a0 | \u00a0 | 30,872 | \u00a0 | \u00a0 | \u00a0 | 24,045 | \u00a0 |
| Dried cannabis | \u00a0 | \u00a0 | 110,315 | \u00a0 | \u00a0 | \u00a0 | 103,507 | \u00a0 |
| Cannabis derivatives | \u00a0 | \u00a0 | 4,227 | \u00a0 | \u00a0 | \u00a0 | 7,877 | \u00a0 |
| Cannabis vapes | \u00a0 | \u00a0 | 1,747 | \u00a0 | \u00a0 | \u00a0 | 1,860 | \u00a0 |
| Packaging and other inventory items | \u00a0 | \u00a0 | 13,746 | \u00a0 | \u00a0 | \u00a0 | 15,366 | \u00a0 |
| Distribution inventory | \u00a0 | \u00a0 | 49,901 | \u00a0 | \u00a0 | \u00a0 | 38,735 | \u00a0 |
| Wellness inventory | \u00a0 | \u00a0 | 14,071 | \u00a0 | \u00a0 | \u00a0 | 15,527 | \u00a0 |
| Total | \u00a0 | $ | 292,303 | \u00a0 | \u00a0 | $ | 270,882 | \u00a0 |
Note 3. Capital assets
\n\u00a0
\nCapital assets consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Land | \u00a0 | $ | 45,535 | \u00a0 | \u00a0 | $ | 44,529 | \u00a0 |
| Production facilities | \u00a0 | \u00a0 | 422,586 | \u00a0 | \u00a0 | \u00a0 | 407,650 | \u00a0 |
| Equipment | \u00a0 | \u00a0 | 278,873 | \u00a0 | \u00a0 | \u00a0 | 280,585 | \u00a0 |
| Leasehold improvements | \u00a0 | \u00a0 | 21,459 | \u00a0 | \u00a0 | \u00a0 | 20,415 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 38,792 | \u00a0 | \u00a0 | \u00a0 | 40,308 | \u00a0 |
| Construction in progress | \u00a0 | \u00a0 | 12,187 | \u00a0 | \u00a0 | \u00a0 | 11,241 | \u00a0 |
| \u00a0 | \u00a0 | $ | 819,432 | \u00a0 | \u00a0 | $ | 804,728 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (276,424 | ) | \u00a0 | \u00a0 | (236,295 | ) |
| Total | \u00a0 | $ | 543,008 | \u00a0 | \u00a0 | $ | 568,433 | \u00a0 |
\u00a0 \u00a0\u00a0
\nAssets held for sale\u00a0consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Production facilities | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 5,800 | \u00a0 |
| Equipment | \u00a0 | \u00a0 | 979 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Leasehold improvements | \u00a0 | \u00a0 | 493 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 977 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 2,449 | \u00a0 | \u00a0 | $ | 5,800 | \u00a0 |
\u00a0
\nDuring the three months ended\u00a0 February 28, 2026, the Company classified the assets of Atwater Brewing, with a carrying value of\u00a0$2,449\u00a0from its Beverage\u00a0reporting unit, as assets held for sale.\u00a0These assets were\u00a0acquired on September\u202f1,\u202f2024 as part of the transaction referred to as \u201cCraft Acquisition II.\u201d Following management\u2019s\u00a0assessment of facility utilizations, it was determined that such assets\u00a0would be held for sale.\u00a0Assets held for sale are\u00a0measured at the lower of carrying amount and the fair value less costs to sell\u00a0and are\u00a0no\u00a0longer depreciated. Changes in the carrying amount are\u00a0recorded in the consolidated statement of net loss and comprehensive loss. During the three months ended\u00a0 February 28, 2026, the Company also completed the sale of the Fort Collins asset group. The loss on the disposition of assets held for sale are\u00a0recorded in the consolidated statement of loss.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-870","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Land | \u00a0 | $ | 45,535 | \u00a0 | \u00a0 | $ | 44,529 | \u00a0 |
| Production facilities | \u00a0 | \u00a0 | 422,586 | \u00a0 | \u00a0 | \u00a0 | 407,650 | \u00a0 |
| Equipment | \u00a0 | \u00a0 | 278,873 | \u00a0 | \u00a0 | \u00a0 | 280,585 | \u00a0 |
| Leasehold improvements | \u00a0 | \u00a0 | 21,459 | \u00a0 | \u00a0 | \u00a0 | 20,415 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 38,792 | \u00a0 | \u00a0 | \u00a0 | 40,308 | \u00a0 |
| Construction in progress | \u00a0 | \u00a0 | 12,187 | \u00a0 | \u00a0 | \u00a0 | 11,241 | \u00a0 |
| \u00a0 | \u00a0 | $ | 819,432 | \u00a0 | \u00a0 | $ | 804,728 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (276,424 | ) | \u00a0 | \u00a0 | (236,295 | ) |
| Total | \u00a0 | $ | 543,008 | \u00a0 | \u00a0 | $ | 568,433 | \u00a0 |
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Production facilities | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 5,800 | \u00a0 |
| Equipment | \u00a0 | \u00a0 | 979 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Leasehold improvements | \u00a0 | \u00a0 | 493 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 977 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 2,449 | \u00a0 | \u00a0 | $ | 5,800 | \u00a0 |
Note 4. Leases
\n\u00a0
\nThe table below presents the lease-related assets and liabilities recorded on the balance sheet.
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 38,792 | \u00a0 | \u00a0 | $ | 40,308 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 17,939 | \u00a0 | \u00a0 | \u00a0 | 22,279 | \u00a0 |
| Total right-of-use assets | \u00a0 | $ | 56,731 | \u00a0 | \u00a0 | $ | 62,587 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,662 | \u00a0 | \u00a0 | $ | 1,560 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 5,597 | \u00a0 | \u00a0 | \u00a0 | 5,381 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 43,226 | \u00a0 | \u00a0 | \u00a0 | 44,295 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 17,056 | \u00a0 | \u00a0 | \u00a0 | 20,630 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 67,541 | \u00a0 | \u00a0 | $ | 71,866 | \u00a0 |
\u00a0
\nIncluded in total lease liabilities is $985 related to disposal groups classified as held for sale. See Note 3 (Capital Assets).
\n\u00a0
\nThe following table presents the future undiscounted payments associated with lease liabilities as of February 28, 2026:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Operating | \u00a0 | \u00a0 | Finance | \u00a0 | ||
| \u00a0 | \u00a0 | leases | \u00a0 | \u00a0 | leases | \u00a0 | ||
| 2026 (remaining three months) | \u00a0 | $ | 1,943 | \u00a0 | \u00a0 | $ | 1,131 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 7,003 | \u00a0 | \u00a0 | \u00a0 | 4,523 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 5,923 | \u00a0 | \u00a0 | \u00a0 | 4,523 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 2,935 | \u00a0 | \u00a0 | \u00a0 | 4,375 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 10,802 | \u00a0 | \u00a0 | \u00a0 | 66,939 | \u00a0 |
| Total minimum lease payments | \u00a0 | $ | 28,606 | \u00a0 | \u00a0 | $ | 81,491 | \u00a0 |
| Imputed interest | \u00a0 | \u00a0 | (5,953 | ) | \u00a0 | \u00a0 | (36,603 | ) |
| Obligations recognized | \u00a0 | $ | 22,653 | \u00a0 | \u00a0 | $ | 44,888 | \u00a0 |
\u00a0
\n "}]},{"name":"rpt:f-902","factDimensions":{"xbrl:concept":"tlry:LeaseRelatedAssetsAndLiabilitiesTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 38,792 | \u00a0 | \u00a0 | $ | 40,308 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 17,939 | \u00a0 | \u00a0 | \u00a0 | 22,279 | \u00a0 |
| Total right-of-use assets | \u00a0 | $ | 56,731 | \u00a0 | \u00a0 | $ | 62,587 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,662 | \u00a0 | \u00a0 | $ | 1,560 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 5,597 | \u00a0 | \u00a0 | \u00a0 | 5,381 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 43,226 | \u00a0 | \u00a0 | \u00a0 | 44,295 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 17,056 | \u00a0 | \u00a0 | \u00a0 | 20,630 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 67,541 | \u00a0 | \u00a0 | $ | 71,866 | \u00a0 |
| \u00a0 | \u00a0 | Operating | \u00a0 | \u00a0 | Finance | \u00a0 | ||
| \u00a0 | \u00a0 | leases | \u00a0 | \u00a0 | leases | \u00a0 | ||
| 2026 (remaining three months) | \u00a0 | $ | 1,943 | \u00a0 | \u00a0 | $ | 1,131 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 7,003 | \u00a0 | \u00a0 | \u00a0 | 4,523 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 5,923 | \u00a0 | \u00a0 | \u00a0 | 4,523 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 2,935 | \u00a0 | \u00a0 | \u00a0 | 4,375 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 10,802 | \u00a0 | \u00a0 | \u00a0 | 66,939 | \u00a0 |
| Total minimum lease payments | \u00a0 | $ | 28,606 | \u00a0 | \u00a0 | $ | 81,491 | \u00a0 |
| Imputed interest | \u00a0 | \u00a0 | (5,953 | ) | \u00a0 | \u00a0 | (36,603 | ) |
| Obligations recognized | \u00a0 | $ | 22,653 | \u00a0 | \u00a0 | $ | 44,888 | \u00a0 |
Note 5. Intangible Assets
\n\u00a0
\nIntangible assets consisted of the following items:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Customer relationships & distribution channel | \u00a0 | \u00a0 | Licenses, permits & applications | \u00a0 | \u00a0 | Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 2026 | \u00a0 | |
| Cost | \u00a0 | $ | 2,409 | \u00a0 | \u00a0 | $ | 18,432 | \u00a0 | \u00a0 | $ | 16,784 | \u00a0 | \u00a0 | $ | 37,625 | \u00a0 |
| Accumulated amortization | \u00a0 | \u00a0 | (161 | ) | \u00a0 | \u00a0 | (9,113 | ) | \u00a0 | \u00a0 | (5,008 | ) | \u00a0 | \u00a0 | (14,282 | ) |
| Total | \u00a0 | $ | 2,248 | \u00a0 | \u00a0 | $ | 9,319 | \u00a0 | \u00a0 | $ | 11,776 | \u00a0 | \u00a0 | $ | 23,343 | \u00a0 |
\u00a0
\nAs of February 28, 2026, the Company also has the\u00a0following intangible assets which have been fully impaired;\u00a0$444,208 of customer relationships and\u00a0distribution channels, $367,022 of licenses, permits and applications, and $452,530 of intellectual property, trademarks, know-how and brands.\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Customer relationships & distribution channel | \u00a0 | \u00a0 | Licenses, permits & applications | \u00a0 | \u00a0 | Non-compete agreements | \u00a0 | \u00a0 | Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 2025 | \u00a0 | |
| Cost | \u00a0 | $ | 610,240 | \u00a0 | \u00a0 | $ | 387,238 | \u00a0 | \u00a0 | $ | 12,449 | \u00a0 | \u00a0 | $ | 618,514 | \u00a0 | \u00a0 | $ | 1,628,441 | \u00a0 |
| Accumulated amortization | \u00a0 | \u00a0 | (166,032 | ) | \u00a0 | \u00a0 | (9,693 | ) | \u00a0 | \u00a0 | (12,449 | ) | \u00a0 | \u00a0 | (155,084 | ) | \u00a0 | \u00a0 | (343,258 | ) |
| Accumulated impairment losses | \u00a0 | \u00a0 | (444,208 | ) | \u00a0 | \u00a0 | (367,022 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (452,530 | ) | \u00a0 | \u00a0 | (1,263,760 | ) |
| Total | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 10,523 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 10,900 | \u00a0 | \u00a0 | $ | 21,423 | \u00a0 |
\u00a0
\nLicenses, permits & applications are predominantly comprised of multi-period\u00a0sponsorship rights.
\n\u00a0
\nExpected future amortization expense for intangible assets as of\u00a0 February 28, 2026\u00a0is\u00a0as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2026 (remaining three months) | \u00a0 | $ | 1,810 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 7,240 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 6,074 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 2,580 | \u00a0 |
| 2030 | \u00a0 | \u00a0 | 2,580 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 3,059 | \u00a0 |
| Total | \u00a0 | $ | 23,343 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-938","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Customer relationships & distribution channel | \u00a0 | \u00a0 | Licenses, permits & applications | \u00a0 | \u00a0 | Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 2026 | \u00a0 | |
| Cost | \u00a0 | $ | 2,409 | \u00a0 | \u00a0 | $ | 18,432 | \u00a0 | \u00a0 | $ | 16,784 | \u00a0 | \u00a0 | $ | 37,625 | \u00a0 |
| Accumulated amortization | \u00a0 | \u00a0 | (161 | ) | \u00a0 | \u00a0 | (9,113 | ) | \u00a0 | \u00a0 | (5,008 | ) | \u00a0 | \u00a0 | (14,282 | ) |
| Total | \u00a0 | $ | 2,248 | \u00a0 | \u00a0 | $ | 9,319 | \u00a0 | \u00a0 | $ | 11,776 | \u00a0 | \u00a0 | $ | 23,343 | \u00a0 |
| \u00a0 | \u00a0 | Customer relationships & distribution channel | \u00a0 | \u00a0 | Licenses, permits & applications | \u00a0 | \u00a0 | Non-compete agreements | \u00a0 | \u00a0 | Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 2025 | \u00a0 | |
| Cost | \u00a0 | $ | 610,240 | \u00a0 | \u00a0 | $ | 387,238 | \u00a0 | \u00a0 | $ | 12,449 | \u00a0 | \u00a0 | $ | 618,514 | \u00a0 | \u00a0 | $ | 1,628,441 | \u00a0 |
| Accumulated amortization | \u00a0 | \u00a0 | (166,032 | ) | \u00a0 | \u00a0 | (9,693 | ) | \u00a0 | \u00a0 | (12,449 | ) | \u00a0 | \u00a0 | (155,084 | ) | \u00a0 | \u00a0 | (343,258 | ) |
| Accumulated impairment losses | \u00a0 | \u00a0 | (444,208 | ) | \u00a0 | \u00a0 | (367,022 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (452,530 | ) | \u00a0 | \u00a0 | (1,263,760 | ) |
| Total | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 10,523 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 10,900 | \u00a0 | \u00a0 | $ | 21,423 | \u00a0 |
| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2026 (remaining three months) | \u00a0 | $ | 1,810 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 7,240 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 6,074 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 2,580 | \u00a0 |
| 2030 | \u00a0 | \u00a0 | 2,580 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 3,059 | \u00a0 |
| Total | \u00a0 | $ | 23,343 | \u00a0 |
Note 6. Goodwill
\n\u00a0
\nThe following table shows the carrying amount of goodwill by reporting units:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | |
| \u00a0 | \u00a0 | 2026 | \u00a0 | |
| Cannabis Goodwill | \u00a0 | $ | 2,640,669 | \u00a0 |
| Accumulated impairment losses | \u00a0 | \u00a0 | (1,888,319 | ) |
| Total | \u00a0 | $ | 752,350 | \u00a0 |
\u00a0
\n \n| \u00a0 | \u00a0 | Reporting Unit | \u00a0 | \u00a0 | May 31, | \u00a0 | ||||||||||||||
| \u00a0 | \u00a0 | Beverage | \u00a0 | \u00a0 | Cannabis | \u00a0 | \u00a0 | Wellness | \u00a0 | \u00a0 | Distribution | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Goodwill | \u00a0 | $ | 120,802 | \u00a0 | \u00a0 | $ | 2,640,669 | \u00a0 | \u00a0 | $ | 77,470 | \u00a0 | \u00a0 | $ | 4,458 | \u00a0 | \u00a0 | $ | 2,843,399 | \u00a0 |
| Accumulated impairment losses | \u00a0 | \u00a0 | (120,802 | ) | \u00a0 | \u00a0 | (1,897,431 | ) | \u00a0 | \u00a0 | (68,186 | ) | \u00a0 | \u00a0 | (4,235 | ) | \u00a0 | \u00a0 | (2,090,654 | ) |
| Effect of foreign exchange | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 9,112 | \u00a0 | \u00a0 | \u00a0 | (9,284 | ) | \u00a0 | \u00a0 | (223 | ) | \u00a0 | \u00a0 | (395 | ) |
| Total | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 752,350 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 752,350 | \u00a0 |
\u00a0
\nDuring the fiscal quarter ended February\u202f28,\u202f2026, the Company assessed for indicators of impairment and concluded that there were no indicators and accordingly,\u202fno further impairment testing was required and impairment charges were recognized during the period.
\n\u00a0
\nIn the prior year, during the fiscal quarter ended\u00a0 February 28, 2025, based upon a combination of factors including a sustained decline in the Company\u2019s market capitalization stemming from the uncertainty resulting from certain changes in U.S. global economic policy, including slower than anticipated progress in global cannabis legalization and overall declines in the craft beer industry sector,\u00a0the Company concluded that it was\u00a0more likely than\u00a0not,\u00a0that the fair value of our reporting units were\u00a0less than their carrying amounts.\u00a0Accordingly, the Company utilized the income approach, which uses future discounted cash flows, to determine the fair value of each reporting unit. As a result, the Company\u00a0recorded non-cash impairment charges of\u00a0$570,000\u00a0of cannabis goodwill, $100,000\u00a0of beverage goodwill,\u00a0$25,000\u00a0of wellness goodwill and $4,235\u00a0of distribution goodwill for the\u00a0three\u00a0and\u00a0nine\u00a0months ended\u00a0 February 28, 2025.\u00a0The non-cash charge had\u00a0no\u00a0impact on the Company\u2019s compliance with debt covenants at\u00a0 February 28, 2025, its cash flows or available liquidity.
\n\u00a0
\nIn the Company\u2019s cannabis goodwill assessment performed during\u00a0the\u00a0three\u00a0and\u00a0nine\u00a0months ended\u00a0 February 28, 2025, the Company\u00a0used a discount rate of\u00a012.00%,\u00a0a terminal growth rate of\u00a05%, and an average revenue growth rate of\u00a034% over\u00a05\u00a0years, based on an\u00a088% and\u00a040% average probability of\u00a0anticipated EU and U.S. cannabis\u00a0legalization, respectively and/or changes in drug policy in various countries within the next\u00a05\u00a0years. A\u00a01%\u00a0increase in the discount rate would result in an additional $285,000\u00a0in impairment, a\u00a01%\u00a0decrease in the terminal growth rate would result in an additional $210,000\u00a0in impairment,\u00a0a\u00a05%\u00a0decrease in the average growth rate would result in an additional $170,000\u00a0in impairment, a\u00a05%\u00a0decrease in the probability of EU cannabis legalization\u00a0would result in an additional $80,000\u00a0in impairment and a\u00a05%\u00a0decrease in the probability of US cannabis legalization\u00a0would result in an additional $7,000\u00a0in impairment.\u00a0Changes to those probabilities resulting in continued delays in or cessation of legalization of cannabis within the United States and internationally, or adverse regulatory changes to existing legislation, could have an unfavorable impact on the estimated future cash flows, and ultimately, the fair value of the cannabis reporting unit, which\u00a0 may\u00a0result in a material impairment expense recognized in future reporting periods.
\n\u00a0
\nIn the Company\u2019s beverage goodwill assessment performed during\u00a0the\u00a0three\u00a0and\u00a0nine\u00a0months ended\u00a0 February 28, 2025, the Company\u00a0used a discount rate of\u00a09.25%, a terminal growth rate of\u00a02%,\u00a0and an average revenue growth rate of\u00a012% over\u00a05\u00a0years.\u00a0A\u00a01%\u00a0increase in the discount rate would result in an additional $70,000\u00a0in impairment, a\u00a01%\u00a0decrease in the terminal growth rate would result in an additional $50,000\u00a0in impairment and a\u00a01%\u00a0decrease in the average growth rate would result in an additional $40,000\u00a0in impairment.
\n\u00a0
\nIn the Company\u2019s wellness goodwill assessment performed during\u00a0the\u00a0three\u00a0and\u00a0nine\u00a0months ended\u00a0 February 28, 2025, the Company\u00a0used a discount rate of\u00a010.50%, a terminal growth rate of\u00a02%,\u00a0and an average revenue growth rate of\u00a07% over\u00a05\u00a0years.\u00a0A\u00a01%\u00a0increase in the discount rate would result in an additional $5,000\u00a0in impairment, a\u00a01%\u00a0decrease in the terminal growth rate would result in an additional $3,000\u00a0in impairment and a\u00a01%\u00a0decrease in the average growth rate would result in an additional $2,000\u00a0in impairment.
\n\u00a0
\nIn the Company\u2019s distribution\u00a0goodwill assessment performed during\u00a0the\u00a0three\u00a0and\u00a0nine\u00a0months ended\u00a0 February 28, 2025, the Company recorded $4,235\u00a0of impairments which brought the remaining distribution goodwill balance to\u00a0\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-983","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfGoodwillTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | |
| \u00a0 | \u00a0 | 2026 | \u00a0 | |
| Cannabis Goodwill | \u00a0 | $ | 2,640,669 | \u00a0 |
| Accumulated impairment losses | \u00a0 | \u00a0 | (1,888,319 | ) |
| Total | \u00a0 | $ | 752,350 | \u00a0 |
| \u00a0 | \u00a0 | Reporting Unit | \u00a0 | \u00a0 | May 31, | \u00a0 | ||||||||||||||
| \u00a0 | \u00a0 | Beverage | \u00a0 | \u00a0 | Cannabis | \u00a0 | \u00a0 | Wellness | \u00a0 | \u00a0 | Distribution | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Goodwill | \u00a0 | $ | 120,802 | \u00a0 | \u00a0 | $ | 2,640,669 | \u00a0 | \u00a0 | $ | 77,470 | \u00a0 | \u00a0 | $ | 4,458 | \u00a0 | \u00a0 | $ | 2,843,399 | \u00a0 |
| Accumulated impairment losses | \u00a0 | \u00a0 | (120,802 | ) | \u00a0 | \u00a0 | (1,897,431 | ) | \u00a0 | \u00a0 | (68,186 | ) | \u00a0 | \u00a0 | (4,235 | ) | \u00a0 | \u00a0 | (2,090,654 | ) |
| Effect of foreign exchange | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 9,112 | \u00a0 | \u00a0 | \u00a0 | (9,284 | ) | \u00a0 | \u00a0 | (223 | ) | \u00a0 | \u00a0 | (395 | ) |
| Total | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 752,350 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 752,350 | \u00a0 |
Note 7.\u00a0Business\u00a0acquisitions
\n\u00a0\u00a0
\nAcquisition of Craft\u00a0Beverage\u00a0Business Portfolio II
\n\u00a0
\nEffective\u00a0 September 1, 2024,\u00a0the Company acquired\u00a0\u00a0craft beer brands and breweries from Molson Coors Beverage Company\u00a0(\u201cMolson\u201d) including Atwater Brewery,\u00a0Hop Valley Brewing Company,\u00a0Terrapin Beer Co., and\u00a0Revolver Brewing (the \u201cCraft\u00a0Acquisition II\u201d).\u00a0The purpose of the acquisition was to continue broadening Tilray's beverage brand strategy. In consideration for the acquisition, the Company paid a total purchase price\u00a0of $22,979\u00a0in cash, which was\u00a0subject to certain customary post-closing working capital adjustments.
\n\u00a0
\nThe table below summarizes the fair value of the assets acquired and the liabilities assumed for the Craft Acquisition II\u00a0at the effective acquisition date\u00a0as follows:\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 22,979 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 4,869 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,993 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 6,844 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 185 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 20,916 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 1,869 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 1,884 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 38,560 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 11,828 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 354 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 564 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 1,515 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 1,320 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 15,581 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 22,979 | \u00a0 |
\u00a0
\nIn the event that the Craft Acquisition II had occurred on June 1, 2024, the Company would have had, on an unaudited proforma basis, additional net\u00a0revenue of approximately and for the three and nine months ended February 28, 2026 and\u00a0approximately and $13,700 for the\u00a0three and nine months ended February 28, 2025, respectively, and its consolidated net loss and comprehensive net loss\u00a0would have increased by approximately\u00a0 and for the three and nine months ended February 28, 2026 and approximately and $4,000 for the\u00a0three and nine months ended February 28, 2025, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition II.
\n\u00a0
\n\u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-1038","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireBusinessesGross","xbrl:period":"2024-09-01T00:00:00/2024-09-02T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionIIMember"},"factValues":[{"value":"22979000","decimals":-3}]},{"name":"rpt:f-1039","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 22,979 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 4,869 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,993 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 6,844 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 185 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 20,916 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 1,869 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 1,884 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 38,560 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 11,828 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 354 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 564 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 1,515 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 1,320 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 15,581 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 22,979 | \u00a0 |
Note 8. Long term investments
\n\u00a0
\nLong term investments consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Equity investments measured at fair value | \u00a0 | $ | 3,270 | \u00a0 | \u00a0 | $ | 1,972 | \u00a0 |
| Equity investments under measurement alternative | \u00a0 | \u00a0 | 4,364 | \u00a0 | \u00a0 | \u00a0 | 8,160 | \u00a0 |
| Total | \u00a0 | $ | 7,634 | \u00a0 | \u00a0 | $ | 10,132 | \u00a0 |
\u00a0
\nAs of February 28, 2026\u00a0and May 31, 2025, included within equity investment under measurement alternative is an option to acquire a\u00a068% membership interest in\u00a0SH Acquisition\u00a0for $1.00 upon U.S. federal cannabis legalization valued at $4,364 and $8,160 respectively.\u00a0See Note 24\u00a0(Financial risk management and financial instruments).\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1059","factDimensions":{"xbrl:concept":"us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Equity investments measured at fair value | \u00a0 | $ | 3,270 | \u00a0 | \u00a0 | $ | 1,972 | \u00a0 |
| Equity investments under measurement alternative | \u00a0 | \u00a0 | 4,364 | \u00a0 | \u00a0 | \u00a0 | 8,160 | \u00a0 |
| Total | \u00a0 | $ | 7,634 | \u00a0 | \u00a0 | $ | 10,132 | \u00a0 |
Note 9. Bank indebtedness
\n\u00a0
\nAphria Inc., a subsidiary of the Company,\u00a0has an operating line of credit in the amount of which bears interest at the lender\u2019s prime rate plus 75 basis points. As of February 28, 2026, the Company has drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located\u00a0at 265 Talbot St. West, Leamington, Ontario.
\n\u00a0
\nCC Pharma GmbH, a subsidiary of the Company, has \u00a0operating lines of credit in the amounts of\u00a0\u00a0and\u00a0\u00a0These lines\u00a0bear interest at\u00a0Euro Short-Term Rate (\u201cESTR\u201d) plus 2.50% and Euro Interbank Offered Rate (\u201cEURIBOR\u201d) plus 4.00%, respectively. As of February 28, 2026, a total of ($8,834) was drawn down from the total available credit of\u00a0\u00a0The operating line\u00a0of credit for \u00a0is secured by an interest in the inventory of CC Pharma GmbH as well as\u00a0the Densborn, Germany production facility and underlying real property. The operating line of credit for is unsecured.
\n\u00a0
\nOn\u00a0 July 25, 2025,\u00a0the Company\u2019s wholly-owned subsidiary, American Beverage Crafts Group Inc. (\u201cABC Group\u201d), formerly known as\u00a0Four Twenty Corporation, finalized its\u00a0fifth\u00a0amendment (the \u201cAmendment\u201d) to that certain Credit Agreement dated as of\u00a0 June 30, 2023 (the \u201cABC Group Credit Agreement\u201d) by and among the Borrower, Bank of America, N.A., in its capacity as Administrative Agent, and certain other guarantors and lenders party thereto. Specifically, the Amendment amended and restated the ABC Group Credit Agreement to provide for the contribution of the Manitoba Harvest entities\u2019 equity to the Borrower as additional collateral.\u00a0Additionally, the Amendment added financial covenants for (i) minimum consolidated trailing-twelve-months EBITDA for each of the\u00a0four\u00a0quarters, beginning\u00a0 May 31, 2025\u00a0and (ii) minimum liquidity.\u00a0ABC Group has a revolving credit facility of $25,000, which bears interest at SOFR plus an applicable margin. As of\u00a0 February 28, 2026, the Company has drawn\u00a0\u00a0on the revolving line of credit under the ABC Group Credit Agreement.\u00a0
\n "}]},{"name":"rpt:f-1071","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-1072","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroShorttermRateMember"},"factValues":[{"value":"0.025","decimals":3}]},{"name":"rpt:f-1073","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroInterbankOfferedRateMember"},"factValues":[{"value":"0.04","decimals":2}]},{"name":"rpt:f-1074","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"8834000","decimals":-3}]},{"name":"rpt:f-1075","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2025-07-26T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:AmericanBeverageCraftsGroupIncMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"25000000","decimals":-6}]},{"name":"rpt:f-1076","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 10. Accounts payable and accrued liabilities
\n\u00a0
\nAccounts payable and accrued liabilities are comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Trade payables | \u00a0 | $ | 115,333 | \u00a0 | \u00a0 | $ | 107,348 | \u00a0 |
| Accrued liabilities | \u00a0 | \u00a0 | 70,342 | \u00a0 | \u00a0 | \u00a0 | 103,260 | \u00a0 |
| Litigation accruals | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 12,431 | \u00a0 |
| Accrued payroll and employment related taxes | \u00a0 | \u00a0 | 12,702 | \u00a0 | \u00a0 | \u00a0 | 1,436 | \u00a0 |
| Income taxes payable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 58 | \u00a0 |
| Accrued interest | \u00a0 | \u00a0 | 2,444 | \u00a0 | \u00a0 | \u00a0 | 4,193 | \u00a0 |
| Sales taxes payable | \u00a0 | \u00a0 | 11,244 | \u00a0 | \u00a0 | \u00a0 | 6,596 | \u00a0 |
| Total | \u00a0 | $ | 223,996 | \u00a0 | \u00a0 | $ | 235,322 | \u00a0 |
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-1077","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Trade payables | \u00a0 | $ | 115,333 | \u00a0 | \u00a0 | $ | 107,348 | \u00a0 |
| Accrued liabilities | \u00a0 | \u00a0 | 70,342 | \u00a0 | \u00a0 | \u00a0 | 103,260 | \u00a0 |
| Litigation accruals | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 12,431 | \u00a0 |
| Accrued payroll and employment related taxes | \u00a0 | \u00a0 | 12,702 | \u00a0 | \u00a0 | \u00a0 | 1,436 | \u00a0 |
| Income taxes payable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 58 | \u00a0 |
| Accrued interest | \u00a0 | \u00a0 | 2,444 | \u00a0 | \u00a0 | \u00a0 | 4,193 | \u00a0 |
| Sales taxes payable | \u00a0 | \u00a0 | 11,244 | \u00a0 | \u00a0 | \u00a0 | 6,596 | \u00a0 |
| Total | \u00a0 | $ | 223,996 | \u00a0 | \u00a0 | $ | 235,322 | \u00a0 |
Note 11. Long-term debt
\n\u00a0
\nThe following table sets forth the net carrying amount of long-term debt instruments:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Term loan - C$ - Canadian prime plus an applicable margin, -year term, with a -year amortization, repayable in equal quarterly payments due in | \u00a0 | $ | 35,770 | \u00a0 | \u00a0 | $ | 38,690 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,647 | \u00a0 | \u00a0 | \u00a0 | 11,501 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 8,660 | \u00a0 | \u00a0 | \u00a0 | 9,354 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 57 | \u00a0 | \u00a0 | \u00a0 | 157 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 1,924 | \u00a0 | \u00a0 | \u00a0 | 2,020 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 2,047 | \u00a0 | \u00a0 | \u00a0 | 2,546 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ to $, due in | \u00a0 | \u00a0 | 18,858 | \u00a0 | \u00a0 | \u00a0 | 19,418 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 75,375 | \u00a0 | \u00a0 | \u00a0 | 80,438 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 153,338 | \u00a0 | \u00a0 | \u00a0 | 164,124 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (903 | ) | \u00a0 | \u00a0 | (864 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 152,435 | \u00a0 | \u00a0 | \u00a0 | 163,260 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (17,453 | ) | \u00a0 | \u00a0 | (14,767 | ) |
| Total non-current portion of long-term debt | \u00a0 | $ | 134,982 | \u00a0 | \u00a0 | $ | 148,493 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-1095","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtInstrumentsTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| Term loan - C$ - Canadian prime plus an applicable margin, -year term, with a -year amortization, repayable in equal quarterly payments due in | \u00a0 | $ | 35,770 | \u00a0 | \u00a0 | $ | 38,690 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,647 | \u00a0 | \u00a0 | \u00a0 | 11,501 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 8,660 | \u00a0 | \u00a0 | \u00a0 | 9,354 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 57 | \u00a0 | \u00a0 | \u00a0 | 157 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 1,924 | \u00a0 | \u00a0 | \u00a0 | 2,020 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 2,047 | \u00a0 | \u00a0 | \u00a0 | 2,546 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ to $, due in | \u00a0 | \u00a0 | 18,858 | \u00a0 | \u00a0 | \u00a0 | 19,418 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 75,375 | \u00a0 | \u00a0 | \u00a0 | 80,438 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 153,338 | \u00a0 | \u00a0 | \u00a0 | 164,124 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (903 | ) | \u00a0 | \u00a0 | (864 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 152,435 | \u00a0 | \u00a0 | \u00a0 | 163,260 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (17,453 | ) | \u00a0 | \u00a0 | (14,767 | ) |
| Total non-current portion of long-term debt | \u00a0 | $ | 134,982 | \u00a0 | \u00a0 | $ | 148,493 | \u00a0 |
Note 12. Convertible debentures payable
\n\u00a0
\nThe following table sets forth the net carrying amount of the convertible debentures payable:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
\u00a0
\nTLRY 27 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (72,500 | ) | \u00a0 | \u00a0 | (67,500 | ) |
| Unamortized discount | \u00a0 | \u00a0 | (11,732 | ) | \u00a0 | \u00a0 | (18,572 | ) |
| Net carrying amount | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
\u00a0
\nThe TLRY\u00a027\u00a0convertible debentures\u00a0were issued\u00a0on\u00a0 May 30, 2023 and on June 9, 2023 by way of overallotment,\u00a0in the principal amount of $172,500 (the \u201cTLRY 27 Notes\u201d). The TLRY 27 Notes\u00a0bear interest at a rate of\u00a05.20% per annum, payable semi-annually in arrears on\u00a0 June 15\u00a0and\u00a0 December 15\u00a0of each year, and mature on\u00a0 June 15, 2027,\u00a0unless earlier converted. The TLRY 27 Notes are Tilray\u2019s general unsecured obligations and rank senior in right of payment to all of Tilray\u2019s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray\u2019s unsecured indebtedness that is not so subordinated,\u00a0effectively junior in right of payment to any of Tilray\u2019s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray\u2019s current or future subsidiaries.\u00a0Noteholders have the right to convert their TLRY\u00a027\u00a0Notes into shares of Tilray\u2019s Common Stock at their option, at any time, until the close of business on the\u00a0second\u00a0scheduled trading day immediately before\u00a0 June 15, 2027.\u00a0The initial conversion rate is approximately 37.66\u00a0shares per\u00a0$1,000\u00a0principal amount of TLRY\u00a027\u00a0Notes, which represents a conversion price of approximately\u00a0$26.55\u00a0per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
\n\u00a0
\nThe TLRY\u00a027\u00a0Notes are now\u00a0redeemable, in whole and\u00a0not\u00a0in part, at Tilray\u2019s option at any time on or after\u00a0 June 20, 2025\u00a0at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray\u2019s Common Stock exceeds\u00a0130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders\u00a0 may\u00a0require\u00a0Tilray\u00a0to repurchase their TLRY\u00a027\u00a0Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company\u2019s offering of the TLRY\u00a027\u00a0Notes, the Company entered into a share lending agreement with an affiliate of\u00a0Jefferies LLC\u00a0(the \u201cShare Borrower\u201d), pursuant to which it lent\u00a0to the Share Borrower 3,850,000\u00a0shares of the Company\u2019s Common Stock (the \u201cBorrowed Shares\u201d). The Borrowed Shares were newly-issued shares,\u00a0will be held as treasury shares until the expiration or early termination of the share lending agreement\u00a0and may be used by purchasers of the TLRY\u00a027\u00a0Notes\u00a0to sell up to\u00a03,850,000 shares of the Company\u2019s Common Stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY\u00a027\u00a0Notes. The Company did\u00a0not\u00a0receive any proceeds from the sale of the Borrowed Shares.\u00a0
\n\u00a0
\nDuring the\u00a0nine months ended February 28, 2026,\u00a0the Company exchanged an aggregate $5,000 of its TLRY\u00a027\u00a0Notes for cancellation, by issuing 1,259,182\u00a0shares of Common Stock and paying $6 in cash to settle\u00a0accrued interest. Upon exchanging\u00a0the TLRY\u00a027\u00a0Notes, a portion of the\u00a0settlement consideration was allocated to the equity component of the instrument and\u00a0was\u00a0recognized as a $1,158 reduction of additional paid-in capital in the Consolidated Statements of Stockholders\u2019 Equity. Additionally, this repurchase resulted in a gain\u00a0of $495 which was recorded in other non-operating (losses) gains, net as shown in Note\u00a023\u00a0(Non-operating income (expense)).\u00a0Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by 120,969\u00a0shares which were then returned\u00a0as Treasury Stock.\u00a0As of\u00a0 February 28, 2026\u00a0and May 31, 2025, a total of 2,231,884 and\u00a02,343,478\u00a0shares remained outstanding under the\u00a0share lending\u00a0arrangement, respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025.\u00a0
\n\u00a0
\nDuring the three and nine months ended February 28, 2026, the Company recognized interest expense\u00a0of $1,300 and $3,923 and\u00a0accretion of amortized discount interest of $2,013 and\u00a0$5,977 respectively. During the three and nine months ended February 28,\u00a02025, the Company recognized interest expense of $1,957 and $6,332 and accretion of amortized discount interest of $2,766 and $8,751 respectively.\u00a0
\n\u00a0
\nAs of\u00a0 February 28, 2026, there was $100,000 principal outstanding compared to $105,000 principal outstanding as of\u00a0 May 31, 2025 under the TLRY 27 Notes.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1123","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (72,500 | ) | \u00a0 | \u00a0 | (67,500 | ) |
| Unamortized discount | \u00a0 | \u00a0 | (11,732 | ) | \u00a0 | \u00a0 | (18,572 | ) |
| Net carrying amount | \u00a0 | $ | 88,268 | \u00a0 | \u00a0 | $ | 86,428 | \u00a0 |
Note 13. Warrant liability
\n\u00a0
\nBetween\u00a0 September 5, 2025 and September 15,\u00a02025,\u00a0certain holders elected to exercise an aggregate of\u00a0620,900 of the Company\u2019s issued and outstanding warrants in accordance with their terms. Pursuant to the exercise of such warrants, Tilray received\u00a0$2,367\u00a0of cash consideration and delivered\u00a0620,900 shares of common stock to such holders. As of February 28, 2026 and May 31, 2025, there were and 620,900 warrants outstanding respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-1165","factDimensions":{"xbrl:concept":"tlry:ClassOfWarrantOrRightExercised","xbrl:period":"2025-09-05T00:00:00/2025-09-16T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"620900"}]},{"name":"rpt:f-1166","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromWarrantExercises","xbrl:period":"2025-09-05T00:00:00/2025-09-16T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2367000","decimals":-3}]},{"name":"rpt:f-1167","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesWarrantsExercised","xbrl:period":"2025-09-05T00:00:00/2025-09-16T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"620900"}]},{"name":"rpt:f-1168","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2025-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"620900"}]},{"name":"rpt:f-1169","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 14. Stockholders' equity\u00a0
\n\u00a0
\nIssued and outstanding
\n\u00a0
\nPursuant to its Fifth Amended and Restated Certificate of Incorporation, the total number of shares that the Company is authorized to issue is 1,426,000,000 shares, of which 1,416,000,000 shares are Common Stock, and 10,000,000\u00a0shares of which are Preferred Stock (the \u201cPreferred Stock\u201d). As of\u00a0 February 28, 2026, the Company had issued and outstanding 116,546,939 shares of Common Stock, 321,391 shares of Treasury Stock\u00a0(the \u201cTreasury\u00a0Stock\u201d)\u00a0and no\u00a0Preferred Stock. Historically, the Company has issued shares of its Common Stock in\u00a0consideration for acquisitions and other\u00a0strategic transactions, settlement of convertible notes,\u00a0settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.
\n\u00a0
\nDuring the nine months ended February 28, 2026, the Company had the following changes in shares of Common Stock:
\n\u00a0
\n| \u00a0 | a) | 6,777,224\u00a0shares of Common Stock were issued pursuant to\u00a0its At-the-Market (\u201cATM\u201d) program, which generated gross proceeds\u00a0of $76,643 and net proceeds of $73,056, after deducting\u00a0$3,587\u00a0in commissions and other fees associated with these issuances. |
| \u00a0 | b) | 1,259,182\u00a0shares of Common Stock were issued in the amount of $4,800\u00a0to exchange\u00a0the\u00a0aggregate\u00a0principal of $5,000 of its TLRY 27\u00a0Notes for cancellation.\u00a0Upon exchanging\u00a0the TLRY\u00a027\u00a0Notes, a portion of the\u00a0settlement consideration was allocated to the equity component of the instrument and\u00a0was\u00a0recognized as a $1,158\u00a0reduction of additional paid-in capital. Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by approximately 120,969\u00a0shares which were then returned\u00a0as Treasury Stock, see Note 12\u00a0(Convertible debentures payable). |
| \u00a0 | c) | 620,900 shares of Common Stock were issued to settle exercised warrants. |
| \u00a0 | d) | 861,707 shares of Common Stock were issued to settle dividends payable to the non-controlling shareholders of Aphria Diamond in the amount of $14,821. |
| \u00a0 | e) | 980,703 shares of Common Stock were issued in connection with the exercise of previously awarded stock-based compensation awards, net of cancellations. |
| \u00a0 | f) | 20,652 shares of Common Stock were cancelled pursuant to the treatment of fractional shares in connection with the Reverse Stock Split. |
\u00a0
\nDuring the nine months ended February 28, 2026, the Company granted 4,554,321 time-based Restricted Stock Units (\u201cRSUs\u201d).
\n\u00a0
\nDuring the fiscal year ended May 31, 2024, the Company issued (i) 756,615 performance\u2011based restricted stock units (the \u201cPerformance\u2011Based RSUs\u201d) and (ii) an additional performance\u2011based award payable in cash or, at the discretion of the Company\u2019s Compensation Committee, in shares of the Company\u2019s common stock (the \u201cPerformance\u2011Based Elective Settlement Award,\u201d and together with the Performance\u2011Based RSUs, the \u201cPerformance\u2011Based Awards\u201d). The Performance\u2011Based Awards were not considered granted for accounting purposes at the time of issuance because the applicable performance conditions had not yet been established or approved. Accordingly, no compensation expense was recognized within the Consolidated Statements of Loss at that time. During the period from issuance through the quarter ended February 28, 2026, the number of outstanding Performance\u2011Based RSUs was reduced from 756,615 to 744,117 as a result of employee attrition, and the Performance\u2011Based Elective Settlement Awards were also correspondingly reduced.
\n\u00a0
\nIn September 2025, the Company established and approved the relevant performance conditions for the Performance\u2011Based Awards and, as a result, the awards were considered granted for accounting purposes. Beginning in the quarter ended November 30, 2025, the Company commenced recognition of stock\u2011based compensation expense based on the grant\u2011date fair value of the Performance\u2011Based Awards, which is being recognized over the remaining requisite service period. The Company currently expects the Performance\u2011Based Elective Settlement Award to be settled in shares of common stock. Moreover, because the Performance\u2011Based Elective Settlement Award has a fixed monetary value and is settleable in a variable number of shares, it is classified as a liability within the statement of Financial Position. The Performance\u2011Based RSUs are classified as equity awards and are reflected within stockholders\u2019 equity.
\n\u00a0
\nThe Company\u2019s total stock-based compensation expense incurred for\u00a0the\u00a0three and nine months ended February 28, 2026\u00a0was $13,725\u00a0and $31,060\u00a0compared to $4,035\u00a0and $18,189 for the\u00a0three and nine months ended February 28,\u00a02025, respectively.\u00a0
\n\u00a0
\nAll current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1170","factDimensions":{"xbrl:concept":"tlry:SharesAuthorizedTotal","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1426000000"}]},{"name":"rpt:f-1171","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1416000000"}]},{"name":"rpt:f-1172","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesAuthorized","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"10000000"}]},{"name":"rpt:f-1173","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesIssued","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"116546939"}]},{"name":"rpt:f-1174","factDimensions":{"xbrl:concept":"us-gaap:TreasuryStockCommonShares","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"321391"}]},{"name":"rpt:f-1175","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesIssued","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"0","decimals":-3}]},{"name":"rpt:f-1176","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"6777224"}]},{"name":"rpt:f-1177","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"76643000","decimals":-3}]},{"name":"rpt:f-1178","factDimensions":{"xbrl:concept":"tlry:NetProceedsFromIssuanceOfCommonStock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"73056000","decimals":-3}]},{"name":"rpt:f-1179","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"3587000","decimals":-3}]},{"name":"rpt:f-1180","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesRepurchaseOfConvertibleSecurities","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:ConversionOfTlry27NotesToSharesMember"},"factValues":[{"value":"1259182"}]},{"name":"rpt:f-1181","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodValueRepurchaseOfConvertibleSecurities","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:ConversionOfTlry27NotesToSharesMember"},"factValues":[{"value":"4800000","decimals":-5}]},{"name":"rpt:f-1182","factDimensions":{"xbrl:concept":"tlry:DebtInstrumentAmountRepurchased","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:ConversionOfTlry27NotesToSharesMember"},"factValues":[{"value":"5000000","decimals":-6}]},{"name":"rpt:f-1183","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member"},"factValues":[{"value":"1158000","decimals":-3}]},{"name":"rpt:f-1184","factDimensions":{"xbrl:concept":"tlry:SharesReturnedFromShareLendingAgreementTreasuryStock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member"},"factValues":[{"value":"120969"}]},{"name":"rpt:f-1185","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesWarrantsExercised","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"620900"}]},{"name":"rpt:f-1186","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfFinancingLiability","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"861707"}]},{"name":"rpt:f-1187","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfFinancingLiability","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:StatementEquityComponentsAxis":"us-gaap:AdditionalPaidInCapitalMember"},"factValues":[{"value":"14821"}]},{"name":"rpt:f-1188","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"980703"}]},{"name":"rpt:f-1189","factDimensions":{"xbrl:concept":"tlry:StockCancelledDuringPeriodSharesReverseStockSplits","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"20652"}]},{"name":"rpt:f-1190","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"4554321"}]},{"name":"rpt:f-1191","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"756615"}]},{"name":"rpt:f-1192","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber","xbrl:period":"2025-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"756615"}]},{"name":"rpt:f-1193","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"744117"}]},{"name":"rpt:f-1194","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"13725000","decimals":-3}]},{"name":"rpt:f-1195","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"31060000","decimals":-4}]},{"name":"rpt:f-1196","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4035000","decimals":-3}]},{"name":"rpt:f-1197","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-06-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"18189000","decimals":-3}]},{"name":"rpt:f-1198","factDimensions":{"xbrl:concept":"us-gaap:ComprehensiveIncomeNoteTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 15. Accumulated other comprehensive income (loss)
\n\u00a0
\nAccumulated other comprehensive income (loss) is comprised of foreign currency translation gain (loss) as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Total | \u00a0 | |
| \u00a0 | \u00a0 | Foreign | \u00a0 | |
| \u00a0 | \u00a0 | currency | \u00a0 | |
| \u00a0 | \u00a0 | translation | \u00a0 | |
| \u00a0 | \u00a0 | gain (loss) | \u00a0 | |
| Balance May 31, 2024 | \u00a0 | $ | (43,499 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | 3,622 | \u00a0 |
| Balance August 31, 2024 | \u00a0 | $ | (39,877 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (8,080 | ) |
| Balance November 30, 2024 | \u00a0 | $ | (47,957 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (4,978 | ) |
| Balance February 28, 2025 | \u00a0 | $ | (52,935 | ) |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Balance May 31, 2025 | \u00a0 | $ | (43,063 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (167 | ) |
| Balance August 31, 2025 | \u00a0 | $ | (43,230 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | 3,937 | \u00a0 |
| Balance November 30, 2025 | \u00a0 | $ | (39,293 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (4,905 | ) |
| Balance February 28, 2026 | \u00a0 | $ | (44,198 | ) |
\u00a0
\n "}]},{"name":"rpt:f-1199","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Total | \u00a0 | |
| \u00a0 | \u00a0 | Foreign | \u00a0 | |
| \u00a0 | \u00a0 | currency | \u00a0 | |
| \u00a0 | \u00a0 | translation | \u00a0 | |
| \u00a0 | \u00a0 | gain (loss) | \u00a0 | |
| Balance May 31, 2024 | \u00a0 | $ | (43,499 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | 3,622 | \u00a0 |
| Balance August 31, 2024 | \u00a0 | $ | (39,877 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (8,080 | ) |
| Balance November 30, 2024 | \u00a0 | $ | (47,957 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (4,978 | ) |
| Balance February 28, 2025 | \u00a0 | $ | (52,935 | ) |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Balance May 31, 2025 | \u00a0 | $ | (43,063 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (167 | ) |
| Balance August 31, 2025 | \u00a0 | $ | (43,230 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | 3,937 | \u00a0 |
| Balance November 30, 2025 | \u00a0 | $ | (39,293 | ) |
| Other comprehensive income (loss) | \u00a0 | \u00a0 | (4,905 | ) |
| Balance February 28, 2026 | \u00a0 | $ | (44,198 | ) |
Note 16. Non-controlling interests
\n\u00a0
\nThe following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: Enroot (75%), Aphria Diamond (51%), and Colcanna S.A.S. (90%).
\n\u00a0
\nThe following table provides a summary of certain balance sheet information\u00a0before intercompany eliminations\u00a0relating to the above-referenced majority-owned subsidiaries of the Company\u00a0in which there was\u00a0a non-controlling interest as of February 28, 2026:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||
| \u00a0 | \u00a0 | Enroot | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Current assets | \u00a0 | $ | 202 | \u00a0 | \u00a0 | $ | 75,233 | \u00a0 | \u00a0 | $ | 2 | \u00a0 | \u00a0 | $ | 75,437 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 107,522 | \u00a0 | \u00a0 | \u00a0 | 3,759 | \u00a0 | \u00a0 | \u00a0 | 111,281 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | (12 | ) | \u00a0 | \u00a0 | (127,190 | ) | \u00a0 | \u00a0 | (7,115 | ) | \u00a0 | \u00a0 | (134,317 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | (31,504 | ) | \u00a0 | \u00a0 | (1,442 | ) | \u00a0 | \u00a0 | (32,946 | ) | |
| Net assets | \u00a0 | $ | 190 | \u00a0 | \u00a0 | $ | 24,061 | \u00a0 | \u00a0 | $ | (4,796 | ) | \u00a0 | $ | 19,455 | \u00a0 |
\u00a0
\nThe following table provides a summary of certain balance sheet information\u00a0before intercompany eliminations\u00a0relating to the above-referenced majority-owned subsidiaries of the Company\u00a0in which there was\u00a0a non-controlling interest as of May 31, 2025:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 83,390 | \u00a0 | \u00a0 | $ | 20 | \u00a0 | \u00a0 | $ | 83,410 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 114,677 | \u00a0 | \u00a0 | \u00a0 | 3,348 | \u00a0 | \u00a0 | \u00a0 | 118,025 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (126,986 | ) | \u00a0 | \u00a0 | (6,953 | ) | \u00a0 | \u00a0 | (133,939 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (31,720 | ) | \u00a0 | \u00a0 | (1,442 | ) | \u00a0 | \u00a0 | (33,162 | ) |
| Net assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,361 | \u00a0 | \u00a0 | $ | (5,027 | ) | \u00a0 | $ | 34,334 | \u00a0 |
\u00a0
\n \n \nThe following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was\u00a0a non-controlling interest\u00a0for the nine months ended February 28, 2026:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||
| \u00a0 | \u00a0 | Enroot | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Revenue | \u00a0 | $ | 27 | \u00a0 | \u00a0 | $ | 46,946 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 46,973 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | 37 | \u00a0 | \u00a0 | \u00a0 | 37,696 | \u00a0 | \u00a0 | \u00a0 | (653 | ) | \u00a0 | \u00a0 | 37,080 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | (10 | ) | \u00a0 | \u00a0 | 9,250 | \u00a0 | \u00a0 | \u00a0 | 653 | \u00a0 | \u00a0 | \u00a0 | 9,893 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (72 | ) | \u00a0 | \u00a0 | (422 | ) | \u00a0 | \u00a0 | (494 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (10 | ) | \u00a0 | $ | 9,178 | \u00a0 | \u00a0 | $ | 231 | \u00a0 | \u00a0 | $ | 9,399 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (3 | ) | \u00a0 | \u00a0 | 4,497 | \u00a0 | \u00a0 | \u00a0 | 23 | \u00a0 | \u00a0 | \u00a0 | 4,517 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (3 | ) | \u00a0 | $ | 4,497 | \u00a0 | \u00a0 | $ | 23 | \u00a0 | \u00a0 | $ | 4,517 | \u00a0 |
\u00a0
\nThe following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was\u00a0a non-controlling interest\u00a0for the nine months ended February 28,\u00a02025:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 53,608 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 53,608 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | 20,000 | \u00a0 | \u00a0 | \u00a0 | 6 | \u00a0 | \u00a0 | \u00a0 | 39,557 | \u00a0 | \u00a0 | \u00a0 | 62 | \u00a0 | \u00a0 | \u00a0 | 59,625 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | (20,000 | ) | \u00a0 | \u00a0 | (6 | ) | \u00a0 | \u00a0 | 14,051 | \u00a0 | \u00a0 | \u00a0 | (62 | ) | \u00a0 | \u00a0 | (6,017 | ) |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 3 | \u00a0 | \u00a0 | \u00a0 | (1,568 | ) | \u00a0 | \u00a0 | 127 | \u00a0 | \u00a0 | \u00a0 | (1,438 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (20,000 | ) | \u00a0 | $ | (3 | ) | \u00a0 | $ | 12,483 | \u00a0 | \u00a0 | $ | 65 | \u00a0 | \u00a0 | $ | (7,455 | ) |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (6,400 | ) | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | 6,117 | \u00a0 | \u00a0 | \u00a0 | 7 | \u00a0 | \u00a0 | \u00a0 | (277 | ) |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (6,400 | ) | \u00a0 | $ | (1 | ) | \u00a0 | $ | 6,117 | \u00a0 | \u00a0 | $ | 7 | \u00a0 | \u00a0 | $ | (277 | ) |
\u00a0 \u00a0 \u00a0\u00a0
\n "}]},{"name":"rpt:f-1215","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:EnrootMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-1216","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"0.51","decimals":2}]},{"name":"rpt:f-1217","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:ColCannaSASMember"},"factValues":[{"value":"0.90","decimals":1}]},{"name":"rpt:f-1218","factDimensions":{"xbrl:concept":"srt:ScheduleOfCondensedBalanceSheetTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||
| \u00a0 | \u00a0 | Enroot | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Current assets | \u00a0 | $ | 202 | \u00a0 | \u00a0 | $ | 75,233 | \u00a0 | \u00a0 | $ | 2 | \u00a0 | \u00a0 | $ | 75,437 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 107,522 | \u00a0 | \u00a0 | \u00a0 | 3,759 | \u00a0 | \u00a0 | \u00a0 | 111,281 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | (12 | ) | \u00a0 | \u00a0 | (127,190 | ) | \u00a0 | \u00a0 | (7,115 | ) | \u00a0 | \u00a0 | (134,317 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | (31,504 | ) | \u00a0 | \u00a0 | (1,442 | ) | \u00a0 | \u00a0 | (32,946 | ) | |
| Net assets | \u00a0 | $ | 190 | \u00a0 | \u00a0 | $ | 24,061 | \u00a0 | \u00a0 | $ | (4,796 | ) | \u00a0 | $ | 19,455 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 83,390 | \u00a0 | \u00a0 | $ | 20 | \u00a0 | \u00a0 | $ | 83,410 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 114,677 | \u00a0 | \u00a0 | \u00a0 | 3,348 | \u00a0 | \u00a0 | \u00a0 | 118,025 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (126,986 | ) | \u00a0 | \u00a0 | (6,953 | ) | \u00a0 | \u00a0 | (133,939 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (31,720 | ) | \u00a0 | \u00a0 | (1,442 | ) | \u00a0 | \u00a0 | (33,162 | ) |
| Net assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,361 | \u00a0 | \u00a0 | $ | (5,027 | ) | \u00a0 | $ | 34,334 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||
| \u00a0 | \u00a0 | Enroot | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Revenue | \u00a0 | $ | 27 | \u00a0 | \u00a0 | $ | 46,946 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 46,973 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | 37 | \u00a0 | \u00a0 | \u00a0 | 37,696 | \u00a0 | \u00a0 | \u00a0 | (653 | ) | \u00a0 | \u00a0 | 37,080 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | (10 | ) | \u00a0 | \u00a0 | 9,250 | \u00a0 | \u00a0 | \u00a0 | 653 | \u00a0 | \u00a0 | \u00a0 | 9,893 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (72 | ) | \u00a0 | \u00a0 | (422 | ) | \u00a0 | \u00a0 | (494 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (10 | ) | \u00a0 | $ | 9,178 | \u00a0 | \u00a0 | $ | 231 | \u00a0 | \u00a0 | $ | 9,399 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (3 | ) | \u00a0 | \u00a0 | 4,497 | \u00a0 | \u00a0 | \u00a0 | 23 | \u00a0 | \u00a0 | \u00a0 | 4,517 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (3 | ) | \u00a0 | $ | 4,497 | \u00a0 | \u00a0 | $ | 23 | \u00a0 | \u00a0 | $ | 4,517 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | February 28, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2025 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 53,608 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 53,608 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | 20,000 | \u00a0 | \u00a0 | \u00a0 | 6 | \u00a0 | \u00a0 | \u00a0 | 39,557 | \u00a0 | \u00a0 | \u00a0 | 62 | \u00a0 | \u00a0 | \u00a0 | 59,625 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | (20,000 | ) | \u00a0 | \u00a0 | (6 | ) | \u00a0 | \u00a0 | 14,051 | \u00a0 | \u00a0 | \u00a0 | (62 | ) | \u00a0 | \u00a0 | (6,017 | ) |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 3 | \u00a0 | \u00a0 | \u00a0 | (1,568 | ) | \u00a0 | \u00a0 | 127 | \u00a0 | \u00a0 | \u00a0 | (1,438 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | (20,000 | ) | \u00a0 | $ | (3 | ) | \u00a0 | $ | 12,483 | \u00a0 | \u00a0 | $ | 65 | \u00a0 | \u00a0 | $ | (7,455 | ) |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | (6,400 | ) | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | 6,117 | \u00a0 | \u00a0 | \u00a0 | 7 | \u00a0 | \u00a0 | \u00a0 | (277 | ) |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | (6,400 | ) | \u00a0 | $ | (1 | ) | \u00a0 | $ | 6,117 | \u00a0 | \u00a0 | $ | 7 | \u00a0 | \u00a0 | $ | (277 | ) |
Note 17. Income taxes
\n\u00a0
\nThe determination of the Company\u2019s overall effective\u00a0tax\u00a0rate requires significant judgment, the use of estimates, and the interpretation and application of complex\u00a0tax\u00a0laws. The effective\u00a0tax\u00a0rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions.\u00a0Tax\u00a0law changes, increases, and decreases in temporary and permanent differences between book and\u00a0tax\u00a0items, valuation allowances against the deferred tax assets, stock compensation, and the Company\u2019s change in income in each jurisdiction all affect the overall effective\u00a0tax\u00a0rate. It is the Company\u2019s practice to recognize interest and penalties related to uncertain\u00a0tax\u00a0positions in income\u00a0tax\u00a0expense.
\n\u00a0
\nThe Company reported income tax expense of $1,974 and $3,235 for the three and nine months ended February 28, 2026, and\u00a0$1,203 and $4,125 for the three and nine months ended February 28,\u00a02025. The income tax expense\u00a0in the current period varies from the US statutory income tax rate and prior year period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1336","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1974000","decimals":-3}]},{"name":"rpt:f-1337","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3235000","decimals":-3}]},{"name":"rpt:f-1338","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"1203000","decimals":-3}]},{"name":"rpt:f-1339","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2024-06-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4125000","decimals":-3}]},{"name":"rpt:f-1340","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 18. Commitments and contingencies
\n\u00a0
\nPurchase and other commitments
\n\u00a0
\nThe Company has financial commitments\u00a0on long-term debt, refer to Note 11\u00a0(Long-term debt), convertible notes, refer to Note 12\u00a0(Convertible debentures payable), material purchase commitments inclusive of\u00a0multi-period\u00a0sponsorship rights and construction commitments as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | 2029 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 153,338 | \u00a0 | \u00a0 | $ | 17,453 | \u00a0 | \u00a0 | $ | 11,305 | \u00a0 | \u00a0 | $ | 93,692 | \u00a0 | \u00a0 | $ | 3,697 | \u00a0 | \u00a0 | $ | 27,191 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 100,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 100,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 61,930 | \u00a0 | \u00a0 | \u00a0 | 32,529 | \u00a0 | \u00a0 | \u00a0 | 29,401 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Construction commitments | \u00a0 | \u00a0 | 2,536 | \u00a0 | \u00a0 | \u00a0 | 881 | \u00a0 | \u00a0 | \u00a0 | 525 | \u00a0 | \u00a0 | \u00a0 | 551 | \u00a0 | \u00a0 | \u00a0 | 579 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 317,804 | \u00a0 | \u00a0 | $ | 50,863 | \u00a0 | \u00a0 | $ | 41,231 | \u00a0 | \u00a0 | $ | 194,243 | \u00a0 | \u00a0 | $ | 4,276 | \u00a0 | \u00a0 | $ | 27,191 | \u00a0 |
\u00a0
\nLegal proceedings
\n\u00a0
\nIn the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves\u00a0 may\u00a0be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is\u00a0not\u00a0probable or the amount of loss is\u00a0not\u00a0estimable, we do\u00a0not\u00a0accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are\u00a0not\u00a0expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable,\u00a0 may\u00a0be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.
\n\u00a0
\nThere have been no material changes in\u00a0the legal proceedings since\u00a0our Annual Report on Form 10-K\u00a0for the fiscal year ended May 31, 2025\u00a0or subsequent Quarterly Reports on Form\u00a010-Q, except with respect to the legal proceedings disclosed below:
\n\u00a0
\nMMIRF, LLC v. Tilray Brands, Inc., et al.
\n\u00a0
\nOn December 31, 2025, MMIRF, LLC filed a complaint in the Superior Court of California, Los Angeles County, against Tilray Brands, Inc., Serruya Private Equity Inc., Superhero Acquisition Corp., Superhero Acquisition L.P., Irwin Simon, Michael Serruya, and Denise Faltischek, asserting claims for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, and civil conspiracy against all defendants.\u00a0The plaintiff allegedly is an assignee of claims previously possessed by MM CAN USA, Inc., a former subsidiary of MedMen Enterprises, Inc. (\u201cMedMen\u201d).\u00a0The complaint alleges that, following a series of transactions in August 2021 pursuant to which Tilray (and other investors) acquired an interest in senior secured convertible notes of MedMen through its investment in Superhero Acquisition L.P. as a limited partner (as previously disclosed in a current report filed on Form 8-K on August 17, 2021), Tilray and the other defendants gained \u201cde facto\u201d control over, and thereby became fiduciaries of, MedMen.\u00a0The complaint further alleges that the defendants breached those purported fiduciary duties in taking certain actions that detrimentally impacted MedMen\u2019s business, which ultimately entered bankruptcy and receivership proceedings in April 2024. The plaintiff seeks damages in excess of $1.0 billion. The defendants\u2019 deadline to move, answer, or otherwise respond to the complaint is currently March 30, 2026. Tilray intends to vigorously defend against the claims asserted in the complaint.\u00a0Based on the information available as of the date of this Quarterly Report, management does not believe that a loss is probable or reasonably estimable, and accordingly no accrual has been recorded.
\n\u00a0
\nSummary of litigation accruals\u00a0
\n\u00a0
\nAs described in Note 10\u00a0(Accounts payable and accrued liabilities), the total estimated litigation\u00a0expense accrual included in accrued liabilities as of\u00a0 February 28, 2026\u00a0and May 31, 2025\u00a0was\u00a0$11,931\u00a0and\u00a0$12,431, respectively. During the intervening period, the accrual decreased by $410 from settled claims and decreased\u00a0$90 due to a net change in the estimated likelihood of certain claim\u2019s settlement, with the remaining change attributable to foreign exchange effects. This estimated accrual is intended to cover various ongoing litigation matters with probable losses that can be reasonably estimated.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1341","factDimensions":{"xbrl:concept":"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | 2029 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 153,338 | \u00a0 | \u00a0 | $ | 17,453 | \u00a0 | \u00a0 | $ | 11,305 | \u00a0 | \u00a0 | $ | 93,692 | \u00a0 | \u00a0 | $ | 3,697 | \u00a0 | \u00a0 | $ | 27,191 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 100,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 100,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 61,930 | \u00a0 | \u00a0 | \u00a0 | 32,529 | \u00a0 | \u00a0 | \u00a0 | 29,401 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Construction commitments | \u00a0 | \u00a0 | 2,536 | \u00a0 | \u00a0 | \u00a0 | 881 | \u00a0 | \u00a0 | \u00a0 | 525 | \u00a0 | \u00a0 | \u00a0 | 551 | \u00a0 | \u00a0 | \u00a0 | 579 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 317,804 | \u00a0 | \u00a0 | $ | 50,863 | \u00a0 | \u00a0 | $ | 41,231 | \u00a0 | \u00a0 | $ | 194,243 | \u00a0 | \u00a0 | $ | 4,276 | \u00a0 | \u00a0 | $ | 27,191 | \u00a0 |
Note 19. Net revenue
\n\u00a0
\nThe Company reports Net revenue in\u00a0\u00a0reporting segments: beverage, cannabis, distribution, and wellness. Net revenue for the\u00a0three and nine months ended February 28, 2026\u00a0and three and nine months ended February 28,\u00a02025\u00a0were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage revenue | \u00a0 | $ | 44,524 | \u00a0 | \u00a0 | $ | 58,009 | \u00a0 | \u00a0 | $ | 156,588 | \u00a0 | \u00a0 | $ | 184,033 | \u00a0 |
| Beverage excise taxes | \u00a0 | \u00a0 | (1,966 | ) | \u00a0 | \u00a0 | (2,088 | ) | \u00a0 | \u00a0 | (8,208 | ) | \u00a0 | \u00a0 | (9,059 | ) |
| Net beverage revenue | \u00a0 | \u00a0 | 42,558 | \u00a0 | \u00a0 | \u00a0 | 55,921 | \u00a0 | \u00a0 | \u00a0 | 148,380 | \u00a0 | \u00a0 | \u00a0 | 174,974 | \u00a0 |
| Cannabis revenue | \u00a0 | \u00a0 | 83,835 | \u00a0 | \u00a0 | \u00a0 | 72,982 | \u00a0 | \u00a0 | \u00a0 | 261,778 | \u00a0 | \u00a0 | \u00a0 | 241,384 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (19,007 | ) | \u00a0 | \u00a0 | (18,708 | ) | \u00a0 | \u00a0 | (64,907 | ) | \u00a0 | \u00a0 | (60,209 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 64,828 | \u00a0 | \u00a0 | \u00a0 | 54,274 | \u00a0 | \u00a0 | \u00a0 | 196,871 | \u00a0 | \u00a0 | \u00a0 | 181,175 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 82,963 | \u00a0 | \u00a0 | \u00a0 | 61,493 | \u00a0 | \u00a0 | \u00a0 | 242,286 | \u00a0 | \u00a0 | \u00a0 | 197,175 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 16,383 | \u00a0 | \u00a0 | \u00a0 | 14,092 | \u00a0 | \u00a0 | \u00a0 | 46,203 | \u00a0 | \u00a0 | \u00a0 | 43,450 | \u00a0 |
| Total | \u00a0 | $ | 206,732 | \u00a0 | \u00a0 | $ | 185,780 | \u00a0 | \u00a0 | $ | 633,740 | \u00a0 | \u00a0 | $ | 596,774 | \u00a0 |
\u00a0\u00a0
\n "}]},{"name":"rpt:f-1378","factDimensions":{"xbrl:concept":"us-gaap:DisaggregationOfRevenueTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage revenue | \u00a0 | $ | 44,524 | \u00a0 | \u00a0 | $ | 58,009 | \u00a0 | \u00a0 | $ | 156,588 | \u00a0 | \u00a0 | $ | 184,033 | \u00a0 |
| Beverage excise taxes | \u00a0 | \u00a0 | (1,966 | ) | \u00a0 | \u00a0 | (2,088 | ) | \u00a0 | \u00a0 | (8,208 | ) | \u00a0 | \u00a0 | (9,059 | ) |
| Net beverage revenue | \u00a0 | \u00a0 | 42,558 | \u00a0 | \u00a0 | \u00a0 | 55,921 | \u00a0 | \u00a0 | \u00a0 | 148,380 | \u00a0 | \u00a0 | \u00a0 | 174,974 | \u00a0 |
| Cannabis revenue | \u00a0 | \u00a0 | 83,835 | \u00a0 | \u00a0 | \u00a0 | 72,982 | \u00a0 | \u00a0 | \u00a0 | 261,778 | \u00a0 | \u00a0 | \u00a0 | 241,384 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (19,007 | ) | \u00a0 | \u00a0 | (18,708 | ) | \u00a0 | \u00a0 | (64,907 | ) | \u00a0 | \u00a0 | (60,209 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 64,828 | \u00a0 | \u00a0 | \u00a0 | 54,274 | \u00a0 | \u00a0 | \u00a0 | 196,871 | \u00a0 | \u00a0 | \u00a0 | 181,175 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 82,963 | \u00a0 | \u00a0 | \u00a0 | 61,493 | \u00a0 | \u00a0 | \u00a0 | 242,286 | \u00a0 | \u00a0 | \u00a0 | 197,175 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 16,383 | \u00a0 | \u00a0 | \u00a0 | 14,092 | \u00a0 | \u00a0 | \u00a0 | 46,203 | \u00a0 | \u00a0 | \u00a0 | 43,450 | \u00a0 |
| Total | \u00a0 | $ | 206,732 | \u00a0 | \u00a0 | $ | 185,780 | \u00a0 | \u00a0 | $ | 633,740 | \u00a0 | \u00a0 | $ | 596,774 | \u00a0 |
Note 20. Cost of goods sold
\n\u00a0
\nThe Company reports Cost of goods sold in\u00a0\u00a0reporting segments: beverage, cannabis, distribution, and wellness.\u00a0Cost of goods sold for the\u00a0three and nine months ended February 28, 2026\u00a0and three and nine months ended February 28,\u00a02025\u00a0were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage costs | \u00a0 | \u00a0 | 28,977 | \u00a0 | \u00a0 | \u00a0 | 35,986 | \u00a0 | \u00a0 | \u00a0 | 97,741 | \u00a0 | \u00a0 | $ | 106,961 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 38,858 | \u00a0 | \u00a0 | \u00a0 | 32,275 | \u00a0 | \u00a0 | \u00a0 | 121,497 | \u00a0 | \u00a0 | \u00a0 | 111,804 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 72,951 | \u00a0 | \u00a0 | \u00a0 | 55,936 | \u00a0 | \u00a0 | \u00a0 | 213,293 | \u00a0 | \u00a0 | \u00a0 | 175,281 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,992 | \u00a0 | \u00a0 | \u00a0 | 9,572 | \u00a0 | \u00a0 | \u00a0 | 31,289 | \u00a0 | \u00a0 | \u00a0 | 29,791 | \u00a0 |
| Total | \u00a0 | $ | 151,778 | \u00a0 | \u00a0 | $ | 133,769 | \u00a0 | \u00a0 | $ | 463,820 | \u00a0 | \u00a0 | $ | 423,837 | \u00a0 |
\u00a0 \u00a0 \u00a0
\n "}]},{"name":"rpt:f-1416","factDimensions":{"xbrl:concept":"tlry:ScheduleOfCostOfGoodsSoldTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage costs | \u00a0 | \u00a0 | 28,977 | \u00a0 | \u00a0 | \u00a0 | 35,986 | \u00a0 | \u00a0 | \u00a0 | 97,741 | \u00a0 | \u00a0 | $ | 106,961 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 38,858 | \u00a0 | \u00a0 | \u00a0 | 32,275 | \u00a0 | \u00a0 | \u00a0 | 121,497 | \u00a0 | \u00a0 | \u00a0 | 111,804 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 72,951 | \u00a0 | \u00a0 | \u00a0 | 55,936 | \u00a0 | \u00a0 | \u00a0 | 213,293 | \u00a0 | \u00a0 | \u00a0 | 175,281 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,992 | \u00a0 | \u00a0 | \u00a0 | 9,572 | \u00a0 | \u00a0 | \u00a0 | 31,289 | \u00a0 | \u00a0 | \u00a0 | 29,791 | \u00a0 |
| Total | \u00a0 | $ | 151,778 | \u00a0 | \u00a0 | $ | 133,769 | \u00a0 | \u00a0 | $ | 463,820 | \u00a0 | \u00a0 | $ | 423,837 | \u00a0 |
Note 21. General and administrative expenses
\n\u00a0
\nGeneral and administrative expenses\u00a0for the\u00a0three and nine months ended February 28, 2026\u00a0and three and nine months ended February 28,\u00a02025\u00a0were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Salaries and wages | \u00a0 | $ | 21,925 | \u00a0 | \u00a0 | \u00a0 | 21,908 | \u00a0 | \u00a0 | $ | 68,425 | \u00a0 | \u00a0 | $ | 66,201 | \u00a0 |
| Office and general | \u00a0 | \u00a0 | 9,916 | \u00a0 | \u00a0 | \u00a0 | 7,385 | \u00a0 | \u00a0 | \u00a0 | 26,897 | \u00a0 | \u00a0 | \u00a0 | 26,103 | \u00a0 |
| Stock-based compensation | \u00a0 | \u00a0 | 13,725 | \u00a0 | \u00a0 | \u00a0 | 4,035 | \u00a0 | \u00a0 | \u00a0 | 31,060 | \u00a0 | \u00a0 | \u00a0 | 18,189 | \u00a0 |
| Insurance | \u00a0 | \u00a0 | 1,894 | \u00a0 | \u00a0 | \u00a0 | 2,942 | \u00a0 | \u00a0 | \u00a0 | 6,743 | \u00a0 | \u00a0 | \u00a0 | 8,552 | \u00a0 |
| Professional fees | \u00a0 | \u00a0 | 1,090 | \u00a0 | \u00a0 | \u00a0 | 1,352 | \u00a0 | \u00a0 | \u00a0 | 3,342 | \u00a0 | \u00a0 | \u00a0 | 3,656 | \u00a0 |
| Gain on sale of capital assets | \u00a0 | \u00a0 | (118 | ) | \u00a0 | \u00a0 | (202 | ) | \u00a0 | \u00a0 | (493 | ) | \u00a0 | \u00a0 | (733 | ) |
| Travel and accommodation | \u00a0 | \u00a0 | 1,014 | \u00a0 | \u00a0 | \u00a0 | 1,100 | \u00a0 | \u00a0 | \u00a0 | 3,618 | \u00a0 | \u00a0 | \u00a0 | 4,347 | \u00a0 |
| Rent | \u00a0 | \u00a0 | 782 | \u00a0 | \u00a0 | \u00a0 | 726 | \u00a0 | \u00a0 | \u00a0 | 2,864 | \u00a0 | \u00a0 | \u00a0 | 3,041 | \u00a0 |
| Total | \u00a0 | $ | 50,228 | \u00a0 | \u00a0 | $ | 39,246 | \u00a0 | \u00a0 | $ | 142,456 | \u00a0 | \u00a0 | $ | 129,356 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-1438","factDimensions":{"xbrl:concept":"tlry:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Salaries and wages | \u00a0 | $ | 21,925 | \u00a0 | \u00a0 | \u00a0 | 21,908 | \u00a0 | \u00a0 | $ | 68,425 | \u00a0 | \u00a0 | $ | 66,201 | \u00a0 |
| Office and general | \u00a0 | \u00a0 | 9,916 | \u00a0 | \u00a0 | \u00a0 | 7,385 | \u00a0 | \u00a0 | \u00a0 | 26,897 | \u00a0 | \u00a0 | \u00a0 | 26,103 | \u00a0 |
| Stock-based compensation | \u00a0 | \u00a0 | 13,725 | \u00a0 | \u00a0 | \u00a0 | 4,035 | \u00a0 | \u00a0 | \u00a0 | 31,060 | \u00a0 | \u00a0 | \u00a0 | 18,189 | \u00a0 |
| Insurance | \u00a0 | \u00a0 | 1,894 | \u00a0 | \u00a0 | \u00a0 | 2,942 | \u00a0 | \u00a0 | \u00a0 | 6,743 | \u00a0 | \u00a0 | \u00a0 | 8,552 | \u00a0 |
| Professional fees | \u00a0 | \u00a0 | 1,090 | \u00a0 | \u00a0 | \u00a0 | 1,352 | \u00a0 | \u00a0 | \u00a0 | 3,342 | \u00a0 | \u00a0 | \u00a0 | 3,656 | \u00a0 |
| Gain on sale of capital assets | \u00a0 | \u00a0 | (118 | ) | \u00a0 | \u00a0 | (202 | ) | \u00a0 | \u00a0 | (493 | ) | \u00a0 | \u00a0 | (733 | ) |
| Travel and accommodation | \u00a0 | \u00a0 | 1,014 | \u00a0 | \u00a0 | \u00a0 | 1,100 | \u00a0 | \u00a0 | \u00a0 | 3,618 | \u00a0 | \u00a0 | \u00a0 | 4,347 | \u00a0 |
| Rent | \u00a0 | \u00a0 | 782 | \u00a0 | \u00a0 | \u00a0 | 726 | \u00a0 | \u00a0 | \u00a0 | 2,864 | \u00a0 | \u00a0 | \u00a0 | 3,041 | \u00a0 |
| Total | \u00a0 | $ | 50,228 | \u00a0 | \u00a0 | $ | 39,246 | \u00a0 | \u00a0 | $ | 142,456 | \u00a0 | \u00a0 | $ | 129,356 | \u00a0 |
Note 22. Restructuring charges
\n\u00a0
\nIn connection with the integration of certain acquisitions and strategic transactions, the Company has incurred restructuring and exit costs in the amount of\u00a0$4,087\u00a0and $5,921 for the three and nine months ended February 28, 2026, compared to $6,133\u00a0and $17,249 for the\u00a0three and nine months ended February 28,\u00a02025. All restructuring\u00a0plans are approved at the executive level, and their associated expenses are recognized in\u00a0the period in which the plan is\u00a0committed or otherwise incurred.
\n\u00a0
\nWithin the Cannabis segment,\u00a0during\u00a0the\u00a0nine months ended February 28, 2026, the Company incurred restructuring expenses totaling $5,259. These charges included $3,739 associated with the restructuring of the Quebec facility to transition from vegetable cultivation to cannabis cultivation in response to increased\u00a0global cannabis demand,\u00a0$992 related to\u00a0employee termination severance and benefits associated with the reorganization of the Canadian cannabis commercial function, and $177 related to the wind-down of certain non-operating entities.\u00a0Additionally, the Company recognized $351\u00a0related to its Fort Collins, CO partially vacant warehouse that was previously\u00a0held for\u00a0sale and was divested during the three\u00a0months ended February 28, 2026. See Note 3 (capital assets).\u00a0
\n\u00a0
\nDuring the fiscal year ended May 31, 2025, the Company accrued $8,500 of restructuring\u00a0charges related to the closure of Hop Valley and other Project 420\u00a0initiatives within the Beverage segment, of which $7,511 was recognized in the nine months ended February 28, 2026, thereby\u00a0reducing the accrual to $989. In addition, during the three and nine months ended February 28, 2026, the Company incurred $662 of restructuring related expenses associated with Atwater Brewing, primarily related to the asset being classified as held for sale and additional facility restructuring activities. See Note 3 (Capital Assets).
\n\u00a0
\n "}]},{"name":"rpt:f-1476","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4087000","decimals":-3}]},{"name":"rpt:f-1477","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"5921000","decimals":-3}]},{"name":"rpt:f-1478","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-12-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"6133000","decimals":-3}]},{"name":"rpt:f-1479","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2025-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"17249000","decimals":-3}]},{"name":"rpt:f-1480","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"5259000","decimals":-3}]},{"name":"rpt:f-1481","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"tlry:ChangeOfOperationsMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember","srt:StatementGeographicalAxis":"stpr:CA-QC"},"factValues":[{"value":"3739000","decimals":-3}]},{"name":"rpt:f-1482","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"992000","decimals":-3}]},{"name":"rpt:f-1483","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:OtherRestructuringMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"177000","decimals":-3}]},{"name":"rpt:f-1484","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RealEstatePropertiesAxis":"tlry:FortCollinsFacilityMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"351000","decimals":-3}]},{"name":"rpt:f-1485","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2025-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:HopValleyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"8500000","decimals":-5}]},{"name":"rpt:f-1486","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:HopValleyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"7511000","decimals":-3}]},{"name":"rpt:f-1487","factDimensions":{"xbrl:concept":"us-gaap:RestructuringReserveAccrualAdjustment1","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:HopValleyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"989000","decimals":-3}]},{"name":"rpt:f-1488","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2025-12-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AtwaterBreweryMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"662000","decimals":-3}]},{"name":"rpt:f-1489","factDimensions":{"xbrl:concept":"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 23. Non-operating income (expense), net
\n\u00a0
\nNon-operating income (expense), net for the\u00a0three and nine months ended February 28, 2026\u00a0and three and nine months ended February 28,\u00a02025\u00a0were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Change in fair value of warrant liability | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 1,338 | \u00a0 | \u00a0 | $ | (3,495 | ) | \u00a0 | $ | 2,896 | \u00a0 |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | 12,469 | \u00a0 | \u00a0 | \u00a0 | (22,290 | ) | \u00a0 | \u00a0 | 9,070 | \u00a0 | \u00a0 | \u00a0 | (44,206 | ) |
| (Loss) gain on long-term investments | \u00a0 | \u00a0 | (4,143 | ) | \u00a0 | \u00a0 | (5,474 | ) | \u00a0 | \u00a0 | (4,449 | ) | \u00a0 | \u00a0 | (5,540 | ) |
| Unrealized loss on digital assets | \u00a0 | \u00a0 | (214 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (386 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (20 | ) | \u00a0 | \u00a0 | 2,404 | \u00a0 | \u00a0 | \u00a0 | (1,126 | ) | \u00a0 | \u00a0 | 2,219 | \u00a0 |
| Total | \u00a0 | $ | 8,092 | \u00a0 | \u00a0 | $ | (24,022 | ) | \u00a0 | $ | (386 | ) | \u00a0 | $ | (44,631 | ) |
\u00a0
\nThe other non-operating losses\u00a0(gains), net for the\u00a0three and nine months ended February 28, 2026, were\u00a0losses of $20\u00a0and\u00a0$1,126, respectively,\u00a0which were\u00a0mainly\u00a0comprised of a loss of $1,501\u00a0on the change in fair value of assets held for sale related to the Fort Collins, CO partially vacant warehouse, as described in Note 3 (capital assets), offset by a gain of $495 resulting from the exchange transaction of\u00a0the TLRY\u00a027\u00a0Note, as described in Note 12 (Convertible debentures payable).\u00a0
\n "}]},{"name":"rpt:f-1490","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Change in fair value of warrant liability | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 1,338 | \u00a0 | \u00a0 | $ | (3,495 | ) | \u00a0 | $ | 2,896 | \u00a0 |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | 12,469 | \u00a0 | \u00a0 | \u00a0 | (22,290 | ) | \u00a0 | \u00a0 | 9,070 | \u00a0 | \u00a0 | \u00a0 | (44,206 | ) |
| (Loss) gain on long-term investments | \u00a0 | \u00a0 | (4,143 | ) | \u00a0 | \u00a0 | (5,474 | ) | \u00a0 | \u00a0 | (4,449 | ) | \u00a0 | \u00a0 | (5,540 | ) |
| Unrealized loss on digital assets | \u00a0 | \u00a0 | (214 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (386 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (20 | ) | \u00a0 | \u00a0 | 2,404 | \u00a0 | \u00a0 | \u00a0 | (1,126 | ) | \u00a0 | \u00a0 | 2,219 | \u00a0 |
| Total | \u00a0 | $ | 8,092 | \u00a0 | \u00a0 | $ | (24,022 | ) | \u00a0 | $ | (386 | ) | \u00a0 | $ | (44,631 | ) |
Note 24. Financial risk management and financial instruments
\n\u00a0
\nFinancial instruments
\n\u00a0
\nThe Company's classification of its financial instruments is described in Note 3\u00a0(Significant accounting policies) in the Notes to our Annual Financial Statements.
\n\u00a0
\nThe carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.
\n\u00a0
\nOn\u00a0 February 28, 2026\u00a0and\u00a0 May 31, 2025, the Company had long-term debt of $2,047 and $2,546, respectively,\u00a0and the principal portion of convertible debentures payable of $100,000 and $105,000, respectively,\u00a0subject to fixed interest rates. The Company\u2019s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.
\n\u00a0
\n \n \nThe following tables present information about the Company\u2019s assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2026 and\u00a0 May 31, 2025, and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | February 28, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 204,620 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 204,620 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 44,885 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 44,885 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 15,312 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 15,312 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 2,253 | \u00a0 | \u00a0 | \u00a0 | 1,017 | \u00a0 | \u00a0 | \u00a0 | 4,364 | \u00a0 | \u00a0 | \u00a0 | 7,634 | \u00a0 |
| Digital assets | \u00a0 | \u00a0 | 614 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 614 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 267,684 | \u00a0 | \u00a0 | $ | 1,017 | \u00a0 | \u00a0 | $ | 4,364 | \u00a0 | \u00a0 | $ | 273,065 | \u00a0 |
\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 221,666 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 221,666 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 34,697 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 34,697 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 909 | \u00a0 | \u00a0 | \u00a0 | 1,063 | \u00a0 | \u00a0 | \u00a0 | 8,160 | \u00a0 | \u00a0 | \u00a0 | 10,132 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,092 | ) | \u00a0 | \u00a0 | (1,092 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 257,272 | \u00a0 | \u00a0 | $ | 1,063 | \u00a0 | \u00a0 | $ | (7,932 | ) | \u00a0 | $ | 250,403 | \u00a0 |
\u00a0
\nThe Company\u2019s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, digital assets, acquisition-related contingent consideration, and warrant liability.
\n\u00a0
\nDuring the\u00a0nine months ended February 28, 2026, the Company purchased\u00a09.16 units of Bitcoin. Digital assets recorded\u00a0at fair value have quoted prices in active markets for identical assets and are classified as Level\u00a01. The following table presents the Company\u2019s\u00a0digital asset holdings as of February 28, 2026:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Quantity | \u00a0 | \u00a0 | Cost Basis | \u00a0 | \u00a0 | Fair Value | \u00a0 | \u00a0 | Cumulative Unrealized Gain (Loss) | \u00a0 | ||||
| Bitcoin | \u00a0 | \u00a0 | 9.16 | \u00a0 | \u00a0 | $ | 1,000 | \u00a0 | \u00a0 | $ | 614 | \u00a0 | \u00a0 | $ | (386 | ) |
| Total digital assets | \u00a0 | \u00a0 | 9.16 | \u00a0 | \u00a0 | $ | 1,000 | \u00a0 | \u00a0 | $ | 614 | \u00a0 | \u00a0 | $ | (386 | ) |
\u00a0
\nCertain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level\u00a01. The\u00a0Company classified securities with observable inputs as Level\u00a02\u00a0and without a quoted market price as Level\u00a03.
\n\u00a0
\nAs of February 28, 2026\u00a0and May 31, 2025, included within equity investment under measurement alternative is an option to acquire a\u00a068% membership interest in\u00a0SH Acquisition\u00a0for $1.00 upon U.S. federal cannabis legalization valued at $4,364 and respectively. During\u00a0the three\u00a0months ended February 28, 2026, the fair value of this option decreased by $3,796 due to changes in the discounted cash flow model used to value the underlying business. Specifically, projected cash flows associated with retail operations were reduced to as a result of restructuring activities, with the remaining valuation attributable solely to projected brand-related cash flows. The valuation continues to assume a 70% probability of U.S. federal cannabis legalization, which is required for the option to become exercisable, as further described below.
\n\u00a0
\nA portion of the total consideration to be paid in connection with the Company\u2019s acquisition\u00a0of Montauk Brewing Company (\u201cMontauk\u201d) was\u00a0contingent upon the achievement by Montauk of certain financial measures as of December 31, 2025. In the event that Montauk achieved either the pre-determined\u00a0sales volume target or EBITDA target, then $15,000\u00a0of contingent consideration would be deemed earned and payable. If both the sales volume target and the EBITDA target were achieved, an additional $3,000 would be deemed earned and payable for a total contingent consideration payment of $18,000.\u00a0
\n\u00a0
\nFor the year ended, May 31, 2025, the Company assessed the estimated value of the\u00a0contingent consideration liability as $15,000, which was estimated to be achieved based on management\u2019s forecast, applying a\u00a0probability of achievement of\u00a0100% for the sales volume target and\u00a00% on the remaining criteria, which was\u00a0not\u00a0expected to be achieved as EBITDA targets were not forecasted to be met.
\n\u00a0
\nDuring the three months ended August 31, 2025, the Company reassessed the estimated fair value of the contingent consideration liability as based on subsequent information regarding Montauk\u2019s operating results and revised expectations for the remainder of the earn\u2011out period. As a result of lower\u2011than\u2011anticipated sales volumes during the peak selling periods of June, July and August 2025, and the\u00a0loss of certain national retail programs, management concluded that Montauk no longer had a viable path to achieving the sales volume target or the\u00a0EBITDA target\u00a0within the earn\u2011out period. Accordingly, the Company applied a probability of achievement of 0% to the sales volume target and 0% to the remaining criteria. The resulting $15,000\u00a0change in fair value of the contingent consideration liability was recorded within the statement of profit and\u00a0loss\u00a0and\u00a0contributed\u00a0to the Company\u2019s\u00a0net income generated during the period ended August 31, 2025, despite historically reporting a net loss.
\n\u00a0
\nDuring the three\u00a0months ended February 28, 2026, the earn-out period concluded and neither financial measure was achieved. Accordingly, further changes to\u00a0the fair value of the contingent consideration liability were recognized during the three\u00a0months ended February 28, 2026\u00a0as no contingent consideration obligation was\u00a0payable.
\n\u00a0
\nThe fair value measurement was\u00a0based on significant unobservable inputs related to projected operating performance and expected cash outflows and was therefore classified was a Level 3 fair value measurement.
\n\u00a0
\nThe balances of assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows for the period\u00a0ended\u00a0 February 28, 2026:
\n\u00a0
\n \n \n \n| \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | |||
| \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | |||
| Balance, May 31, 2025 | \u00a0 | $ | 8,160 | \u00a0 | \u00a0 | $ | (1,092 | ) | \u00a0 | $ | (15,000 | ) |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | (3,796 | ) | \u00a0 | \u00a0 | (3,495 | ) | \u00a0 | \u00a0 | 15,000 | \u00a0 |
| Instruments exercised | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,587 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, February 28, 2026 | \u00a0 | $ | 4,364 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 |
\u00a0
\nThe balances of assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows for the period\u00a0ended\u00a0 February 28, 2025:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(disposals) | \u00a0 | \u00a0 | (12,000 | ) | \u00a0 | \u00a0 | 8,160 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Redemption | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5,500 | ) | \u00a0 | \u00a0 | 2,896 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | (20,000 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, February 28, 2025 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 8,160 | \u00a0 | \u00a0 | $ | (357 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
\u00a0
\nThe unrealized gain (loss) on assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy are\u00a0recognized in the consolidated statements of loss and comprehensive loss using the following inputs:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | \u00a0 |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Equity investments | \u00a0 | Discounted cash flows | \u00a0 | Probability of achievement | \u00a0 | 70% | \u00a0 |
\u00a0
\nItems measured at fair value on a non-recurring basis
\n\u00a0
\nThe Company\u2019s prepaids and other current assets, long lived assets, including property and equipment, assets held for sale, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.
\n\u00a0
\nCapital and liquidity\u00a0management
\n\u00a0
\nManagement reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company\u2019s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.
\n\u00a0
\n "}]},{"name":"rpt:f-1520","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"2047000","decimals":-3}]},{"name":"rpt:f-1521","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"2546000","decimals":-3}]},{"name":"rpt:f-1522","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2026-03-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"100000000","decimals":-8}]},{"name":"rpt:f-1523","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"105000000","decimals":-6}]},{"name":"rpt:f-1524","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | February 28, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2026 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 204,620 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 204,620 | \u00a0 |
| Restricted cash | \u00a0 | \u00a0 | 44,885 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 44,885 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 15,312 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 15,312 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 2,253 | \u00a0 | \u00a0 | \u00a0 | 1,017 | \u00a0 | \u00a0 | \u00a0 | 4,364 | \u00a0 | \u00a0 | \u00a0 | 7,634 | \u00a0 |
| Digital assets | \u00a0 | \u00a0 | 614 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 614 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 267,684 | \u00a0 | \u00a0 | $ | 1,017 | \u00a0 | \u00a0 | $ | 4,364 | \u00a0 | \u00a0 | $ | 273,065 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 221,666 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 221,666 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 34,697 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 34,697 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 909 | \u00a0 | \u00a0 | \u00a0 | 1,063 | \u00a0 | \u00a0 | \u00a0 | 8,160 | \u00a0 | \u00a0 | \u00a0 | 10,132 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,092 | ) | \u00a0 | \u00a0 | (1,092 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 257,272 | \u00a0 | \u00a0 | $ | 1,063 | \u00a0 | \u00a0 | $ | (7,932 | ) | \u00a0 | $ | 250,403 | \u00a0 |
| \u00a0 | \u00a0 | Quantity | \u00a0 | \u00a0 | Cost Basis | \u00a0 | \u00a0 | Fair Value | \u00a0 | \u00a0 | Cumulative Unrealized Gain (Loss) | \u00a0 | ||||
| Bitcoin | \u00a0 | \u00a0 | 9.16 | \u00a0 | \u00a0 | $ | 1,000 | \u00a0 | \u00a0 | $ | 614 | \u00a0 | \u00a0 | $ | (386 | ) |
| Total digital assets | \u00a0 | \u00a0 | 9.16 | \u00a0 | \u00a0 | $ | 1,000 | \u00a0 | \u00a0 | $ | 614 | \u00a0 | \u00a0 | $ | (386 | ) |
| \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | |||
| \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | |||
| Balance, May 31, 2025 | \u00a0 | $ | 8,160 | \u00a0 | \u00a0 | $ | (1,092 | ) | \u00a0 | $ | (15,000 | ) |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | (3,796 | ) | \u00a0 | \u00a0 | (3,495 | ) | \u00a0 | \u00a0 | 15,000 | \u00a0 |
| Instruments exercised | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,587 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, February 28, 2026 | \u00a0 | $ | 4,364 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(disposals) | \u00a0 | \u00a0 | (12,000 | ) | \u00a0 | \u00a0 | 8,160 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Redemption | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5,500 | ) | \u00a0 | \u00a0 | 2,896 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | (20,000 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, February 28, 2025 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 8,160 | \u00a0 | \u00a0 | $ | (357 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | \u00a0 |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Equity investments | \u00a0 | Discounted cash flows | \u00a0 | Probability of achievement | \u00a0 | 70% | \u00a0 |
Note 25. Segment reporting
\n\u00a0
\nOur Company\u2019s Chief Operating Decision Maker (\u201cCODM\u201d) is the Chairman of the Board of Directors and Chief Executive Officer. The\u00a0CODM uses segment gross profit for the purpose of resource allocation, assessment of segment performance against determined targets, and in deciding whether to implement cost saving targets. The Company operates in\u00a0\u00a0segments.\u00a01) cannabis operations, which encompasses the production, distribution,\u00a0sale, co-manufacturing and advisory services of both medical and adult-use cannabis,\u00a02) beverage operations, which encompasses the production, marketing and sale of beverage products,\u00a03) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and\u00a04) wellness products, which encompasses wellness and better-for-you foods and beverages. This structure is in line with how our CODM assesses our performance and allocates resources.
\n\u00a0
\nOperating segments have\u00a0not\u00a0been aggregated and\u00a0no\u00a0asset information is provided for the segments because the Company\u2019s CODM does\u00a0not\u00a0receive asset information by segment on a regular basis.
\n\u00a0
\nThe following tables reconcile the Company\u2019s segment gross profit\u00a0to consolidated U.S. GAAP results:
\n\u00a0
\n \n \n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage revenue | \u00a0 | $ | 42,558 | \u00a0 | \u00a0 | $ | 55,921 | \u00a0 | \u00a0 | $ | 148,380 | \u00a0 | \u00a0 | $ | 174,974 | \u00a0 |
| Beverage costs | \u00a0 | \u00a0 | 28,977 | \u00a0 | \u00a0 | \u00a0 | 35,986 | \u00a0 | \u00a0 | \u00a0 | 97,741 | \u00a0 | \u00a0 | \u00a0 | 106,961 | \u00a0 |
| Beverage gross profit | \u00a0 | \u00a0 | 13,581 | \u00a0 | \u00a0 | \u00a0 | 19,935 | \u00a0 | \u00a0 | \u00a0 | 50,639 | \u00a0 | \u00a0 | \u00a0 | 68,013 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 64,828 | \u00a0 | \u00a0 | \u00a0 | 54,274 | \u00a0 | \u00a0 | \u00a0 | 196,871 | \u00a0 | \u00a0 | \u00a0 | 181,175 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 38,858 | \u00a0 | \u00a0 | \u00a0 | 32,275 | \u00a0 | \u00a0 | \u00a0 | 121,497 | \u00a0 | \u00a0 | \u00a0 | 111,804 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 25,970 | \u00a0 | \u00a0 | \u00a0 | 21,999 | \u00a0 | \u00a0 | \u00a0 | 75,374 | \u00a0 | \u00a0 | \u00a0 | 69,371 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 82,963 | \u00a0 | \u00a0 | \u00a0 | 61,493 | \u00a0 | \u00a0 | \u00a0 | 242,286 | \u00a0 | \u00a0 | \u00a0 | 197,175 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 72,951 | \u00a0 | \u00a0 | \u00a0 | 55,936 | \u00a0 | \u00a0 | \u00a0 | 213,293 | \u00a0 | \u00a0 | \u00a0 | 175,281 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 10,012 | \u00a0 | \u00a0 | \u00a0 | 5,557 | \u00a0 | \u00a0 | \u00a0 | 28,993 | \u00a0 | \u00a0 | \u00a0 | 21,894 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 16,383 | \u00a0 | \u00a0 | \u00a0 | 14,092 | \u00a0 | \u00a0 | \u00a0 | 46,203 | \u00a0 | \u00a0 | \u00a0 | 43,450 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,992 | \u00a0 | \u00a0 | \u00a0 | 9,572 | \u00a0 | \u00a0 | \u00a0 | 31,289 | \u00a0 | \u00a0 | \u00a0 | 29,791 | \u00a0 |
| Wellness gross profit | \u00a0 | \u00a0 | 5,391 | \u00a0 | \u00a0 | \u00a0 | 4,520 | \u00a0 | \u00a0 | \u00a0 | 14,914 | \u00a0 | \u00a0 | $ | 13,659 | \u00a0 |
| Total | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Total revenue | \u00a0 | \u00a0 | 206,732 | \u00a0 | \u00a0 | \u00a0 | 185,780 | \u00a0 | \u00a0 | \u00a0 | 633,740 | \u00a0 | \u00a0 | \u00a0 | 596,774 | \u00a0 |
| Total costs | \u00a0 | \u00a0 | 151,778 | \u00a0 | \u00a0 | \u00a0 | 133,769 | \u00a0 | \u00a0 | \u00a0 | 463,820 | \u00a0 | \u00a0 | \u00a0 | 423,837 | \u00a0 |
| Total gross profit | \u00a0 | $ | 54,954 | \u00a0 | \u00a0 | $ | 52,011 | \u00a0 | \u00a0 | $ | 169,920 | \u00a0 | \u00a0 | $ | 172,937 | \u00a0 |
\u00a0
\nSegment costs are comprised of cost of goods sold, which include product costs, salaries and an allocation of overhead costs.\u00a0
\n\u00a0
\nThe following table reconciles the total segment gross profit\u00a0to the Company\u2019s consolidated totals:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Gross profit | \u00a0 | $ | 54,954 | \u00a0 | \u00a0 | $ | 52,011 | \u00a0 | \u00a0 | $ | 169,920 | \u00a0 | \u00a0 | $ | 172,937 | \u00a0 |
| Operating expenses: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| General and administrative | \u00a0 | \u00a0 | 50,228 | \u00a0 | \u00a0 | \u00a0 | 39,246 | \u00a0 | \u00a0 | \u00a0 | 142,456 | \u00a0 | \u00a0 | \u00a0 | 129,356 | \u00a0 |
| Selling | \u00a0 | \u00a0 | 10,617 | \u00a0 | \u00a0 | \u00a0 | 13,905 | \u00a0 | \u00a0 | \u00a0 | 35,321 | \u00a0 | \u00a0 | \u00a0 | 41,757 | \u00a0 |
| Amortization | \u00a0 | \u00a0 | 5,106 | \u00a0 | \u00a0 | \u00a0 | 23,182 | \u00a0 | \u00a0 | \u00a0 | 13,393 | \u00a0 | \u00a0 | \u00a0 | 67,913 | \u00a0 |
| Marketing and promotion | \u00a0 | \u00a0 | 8,692 | \u00a0 | \u00a0 | \u00a0 | 6,793 | \u00a0 | \u00a0 | \u00a0 | 28,828 | \u00a0 | \u00a0 | \u00a0 | 28,079 | \u00a0 |
| Research and development | \u00a0 | \u00a0 | 62 | \u00a0 | \u00a0 | \u00a0 | 85 | \u00a0 | \u00a0 | \u00a0 | 181 | \u00a0 | \u00a0 | \u00a0 | 250 | \u00a0 |
| Change in fair value of contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairment of intangible assets and goodwill | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 699,235 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 699,235 | \u00a0 |
| Other than temporary change in fair value of convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 20,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 20,000 | \u00a0 |
| Litigation costs, net of recoveries | \u00a0 | \u00a0 | 621 | \u00a0 | \u00a0 | \u00a0 | 2,758 | \u00a0 | \u00a0 | \u00a0 | 2,497 | \u00a0 | \u00a0 | \u00a0 | 5,254 | \u00a0 |
| Restructuring costs | \u00a0 | \u00a0 | 4,087 | \u00a0 | \u00a0 | \u00a0 | 6,133 | \u00a0 | \u00a0 | \u00a0 | 5,921 | \u00a0 | \u00a0 | \u00a0 | 17,249 | \u00a0 |
| Transaction costs (income), net | \u00a0 | \u00a0 | 1,927 | \u00a0 | \u00a0 | \u00a0 | 605 | \u00a0 | \u00a0 | \u00a0 | 2,896 | \u00a0 | \u00a0 | \u00a0 | 2,563 | \u00a0 |
| Total operating expenses | \u00a0 | \u00a0 | 81,340 | \u00a0 | \u00a0 | \u00a0 | 811,942 | \u00a0 | \u00a0 | \u00a0 | 216,493 | \u00a0 | \u00a0 | \u00a0 | 1,011,656 | \u00a0 |
| Operating loss | \u00a0 | \u00a0 | (26,386 | ) | \u00a0 | \u00a0 | (759,931 | ) | \u00a0 | \u00a0 | (46,573 | ) | \u00a0 | \u00a0 | (838,719 | ) |
| Interest expense, net | \u00a0 | \u00a0 | (4,965 | ) | \u00a0 | \u00a0 | (8,378 | ) | \u00a0 | \u00a0 | (17,035 | ) | \u00a0 | \u00a0 | (25,986 | ) |
| Non-operating income (expense), net | \u00a0 | \u00a0 | 8,092 | \u00a0 | \u00a0 | \u00a0 | (24,022 | ) | \u00a0 | \u00a0 | (386 | ) | \u00a0 | \u00a0 | (44,631 | ) |
| Loss before income taxes | \u00a0 | \u00a0 | (23,259 | ) | \u00a0 | \u00a0 | (792,331 | ) | \u00a0 | \u00a0 | (63,994 | ) | \u00a0 | \u00a0 | (909,336 | ) |
| Income tax expense (recovery), net | \u00a0 | \u00a0 | 1,974 | \u00a0 | \u00a0 | \u00a0 | 1,203 | \u00a0 | \u00a0 | \u00a0 | 3,235 | \u00a0 | \u00a0 | \u00a0 | 4,125 | \u00a0 |
| Net loss | \u00a0 | $ | (25,233 | ) | \u00a0 | $ | (793,534 | ) | \u00a0 | $ | (67,229 | ) | \u00a0 | $ | (913,461 | ) |
\u00a0
\nChannels of Cannabis revenue were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 5,979 | \u00a0 | \u00a0 | $ | 5,839 | \u00a0 | \u00a0 | $ | 18,359 | \u00a0 | \u00a0 | $ | 18,773 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 52,570 | \u00a0 | \u00a0 | \u00a0 | 49,315 | \u00a0 | \u00a0 | \u00a0 | 179,085 | \u00a0 | \u00a0 | \u00a0 | 165,627 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 1,165 | \u00a0 | \u00a0 | \u00a0 | 3,893 | \u00a0 | \u00a0 | \u00a0 | 6,666 | \u00a0 | \u00a0 | \u00a0 | 15,993 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 24,121 | \u00a0 | \u00a0 | \u00a0 | 13,935 | \u00a0 | \u00a0 | \u00a0 | 57,668 | \u00a0 | \u00a0 | \u00a0 | 40,991 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (19,007 | ) | \u00a0 | \u00a0 | (18,708 | ) | \u00a0 | \u00a0 | (64,907 | ) | \u00a0 | \u00a0 | (60,209 | ) |
| Total | \u00a0 | $ | 64,828 | \u00a0 | \u00a0 | $ | 54,274 | \u00a0 | \u00a0 | $ | 196,871 | \u00a0 | \u00a0 | $ | 181,175 | \u00a0 |
\u00a0
\n \n \nGeographic net revenue:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| USA | \u00a0 | $ | 51,683 | \u00a0 | \u00a0 | $ | 64,420 | \u00a0 | \u00a0 | $ | 173,482 | \u00a0 | \u00a0 | $ | 200,053 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 48,221 | \u00a0 | \u00a0 | \u00a0 | 45,930 | \u00a0 | \u00a0 | \u00a0 | 160,561 | \u00a0 | \u00a0 | \u00a0 | 158,555 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 104,955 | \u00a0 | \u00a0 | \u00a0 | 72,386 | \u00a0 | \u00a0 | \u00a0 | 293,363 | \u00a0 | \u00a0 | \u00a0 | 229,312 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 1,873 | \u00a0 | \u00a0 | \u00a0 | 3,044 | \u00a0 | \u00a0 | \u00a0 | 6,334 | \u00a0 | \u00a0 | \u00a0 | 8,854 | \u00a0 |
| Total | \u00a0 | $ | 206,732 | \u00a0 | \u00a0 | $ | 185,780 | \u00a0 | \u00a0 | $ | 633,740 | \u00a0 | \u00a0 | $ | 596,774 | \u00a0 |
\u00a0
\nGeographic capital assets:
\n\u00a0
\n \n| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| USA | \u00a0 | $ | 188,500 | \u00a0 | \u00a0 | $ | 200,003 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 251,645 | \u00a0 | \u00a0 | \u00a0 | 267,458 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 98,571 | \u00a0 | \u00a0 | \u00a0 | 97,371 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 4,292 | \u00a0 | \u00a0 | \u00a0 | 3,601 | \u00a0 |
| Total | \u00a0 | $ | 543,008 | \u00a0 | \u00a0 | $ | 568,433 | \u00a0 |
\u00a0
\nMajor customers are defined as customers that are materially significant\u00a0to the Company\u2019s annual revenues. For the three and nine months ended February 28, 2026 and 2025, there were no major customers representing a material contribution\u00a0to\u00a0our quarterly revenues.
\n "}]},{"name":"rpt:f-1644","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Beverage | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage revenue | \u00a0 | $ | 42,558 | \u00a0 | \u00a0 | $ | 55,921 | \u00a0 | \u00a0 | $ | 148,380 | \u00a0 | \u00a0 | $ | 174,974 | \u00a0 |
| Beverage costs | \u00a0 | \u00a0 | 28,977 | \u00a0 | \u00a0 | \u00a0 | 35,986 | \u00a0 | \u00a0 | \u00a0 | 97,741 | \u00a0 | \u00a0 | \u00a0 | 106,961 | \u00a0 |
| Beverage gross profit | \u00a0 | \u00a0 | 13,581 | \u00a0 | \u00a0 | \u00a0 | 19,935 | \u00a0 | \u00a0 | \u00a0 | 50,639 | \u00a0 | \u00a0 | \u00a0 | 68,013 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 64,828 | \u00a0 | \u00a0 | \u00a0 | 54,274 | \u00a0 | \u00a0 | \u00a0 | 196,871 | \u00a0 | \u00a0 | \u00a0 | 181,175 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 38,858 | \u00a0 | \u00a0 | \u00a0 | 32,275 | \u00a0 | \u00a0 | \u00a0 | 121,497 | \u00a0 | \u00a0 | \u00a0 | 111,804 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 25,970 | \u00a0 | \u00a0 | \u00a0 | 21,999 | \u00a0 | \u00a0 | \u00a0 | 75,374 | \u00a0 | \u00a0 | \u00a0 | 69,371 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 82,963 | \u00a0 | \u00a0 | \u00a0 | 61,493 | \u00a0 | \u00a0 | \u00a0 | 242,286 | \u00a0 | \u00a0 | \u00a0 | 197,175 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 72,951 | \u00a0 | \u00a0 | \u00a0 | 55,936 | \u00a0 | \u00a0 | \u00a0 | 213,293 | \u00a0 | \u00a0 | \u00a0 | 175,281 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 10,012 | \u00a0 | \u00a0 | \u00a0 | 5,557 | \u00a0 | \u00a0 | \u00a0 | 28,993 | \u00a0 | \u00a0 | \u00a0 | 21,894 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 16,383 | \u00a0 | \u00a0 | \u00a0 | 14,092 | \u00a0 | \u00a0 | \u00a0 | 46,203 | \u00a0 | \u00a0 | \u00a0 | 43,450 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,992 | \u00a0 | \u00a0 | \u00a0 | 9,572 | \u00a0 | \u00a0 | \u00a0 | 31,289 | \u00a0 | \u00a0 | \u00a0 | 29,791 | \u00a0 |
| Wellness gross profit | \u00a0 | \u00a0 | 5,391 | \u00a0 | \u00a0 | \u00a0 | 4,520 | \u00a0 | \u00a0 | \u00a0 | 14,914 | \u00a0 | \u00a0 | $ | 13,659 | \u00a0 |
| Total | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Total revenue | \u00a0 | \u00a0 | 206,732 | \u00a0 | \u00a0 | \u00a0 | 185,780 | \u00a0 | \u00a0 | \u00a0 | 633,740 | \u00a0 | \u00a0 | \u00a0 | 596,774 | \u00a0 |
| Total costs | \u00a0 | \u00a0 | 151,778 | \u00a0 | \u00a0 | \u00a0 | 133,769 | \u00a0 | \u00a0 | \u00a0 | 463,820 | \u00a0 | \u00a0 | \u00a0 | 423,837 | \u00a0 |
| Total gross profit | \u00a0 | $ | 54,954 | \u00a0 | \u00a0 | $ | 52,011 | \u00a0 | \u00a0 | $ | 169,920 | \u00a0 | \u00a0 | $ | 172,937 | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Gross profit | \u00a0 | $ | 54,954 | \u00a0 | \u00a0 | $ | 52,011 | \u00a0 | \u00a0 | $ | 169,920 | \u00a0 | \u00a0 | $ | 172,937 | \u00a0 |
| Operating expenses: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| General and administrative | \u00a0 | \u00a0 | 50,228 | \u00a0 | \u00a0 | \u00a0 | 39,246 | \u00a0 | \u00a0 | \u00a0 | 142,456 | \u00a0 | \u00a0 | \u00a0 | 129,356 | \u00a0 |
| Selling | \u00a0 | \u00a0 | 10,617 | \u00a0 | \u00a0 | \u00a0 | 13,905 | \u00a0 | \u00a0 | \u00a0 | 35,321 | \u00a0 | \u00a0 | \u00a0 | 41,757 | \u00a0 |
| Amortization | \u00a0 | \u00a0 | 5,106 | \u00a0 | \u00a0 | \u00a0 | 23,182 | \u00a0 | \u00a0 | \u00a0 | 13,393 | \u00a0 | \u00a0 | \u00a0 | 67,913 | \u00a0 |
| Marketing and promotion | \u00a0 | \u00a0 | 8,692 | \u00a0 | \u00a0 | \u00a0 | 6,793 | \u00a0 | \u00a0 | \u00a0 | 28,828 | \u00a0 | \u00a0 | \u00a0 | 28,079 | \u00a0 |
| Research and development | \u00a0 | \u00a0 | 62 | \u00a0 | \u00a0 | \u00a0 | 85 | \u00a0 | \u00a0 | \u00a0 | 181 | \u00a0 | \u00a0 | \u00a0 | 250 | \u00a0 |
| Change in fair value of contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairment of intangible assets and goodwill | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 699,235 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 699,235 | \u00a0 |
| Other than temporary change in fair value of convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 20,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 20,000 | \u00a0 |
| Litigation costs, net of recoveries | \u00a0 | \u00a0 | 621 | \u00a0 | \u00a0 | \u00a0 | 2,758 | \u00a0 | \u00a0 | \u00a0 | 2,497 | \u00a0 | \u00a0 | \u00a0 | 5,254 | \u00a0 |
| Restructuring costs | \u00a0 | \u00a0 | 4,087 | \u00a0 | \u00a0 | \u00a0 | 6,133 | \u00a0 | \u00a0 | \u00a0 | 5,921 | \u00a0 | \u00a0 | \u00a0 | 17,249 | \u00a0 |
| Transaction costs (income), net | \u00a0 | \u00a0 | 1,927 | \u00a0 | \u00a0 | \u00a0 | 605 | \u00a0 | \u00a0 | \u00a0 | 2,896 | \u00a0 | \u00a0 | \u00a0 | 2,563 | \u00a0 |
| Total operating expenses | \u00a0 | \u00a0 | 81,340 | \u00a0 | \u00a0 | \u00a0 | 811,942 | \u00a0 | \u00a0 | \u00a0 | 216,493 | \u00a0 | \u00a0 | \u00a0 | 1,011,656 | \u00a0 |
| Operating loss | \u00a0 | \u00a0 | (26,386 | ) | \u00a0 | \u00a0 | (759,931 | ) | \u00a0 | \u00a0 | (46,573 | ) | \u00a0 | \u00a0 | (838,719 | ) |
| Interest expense, net | \u00a0 | \u00a0 | (4,965 | ) | \u00a0 | \u00a0 | (8,378 | ) | \u00a0 | \u00a0 | (17,035 | ) | \u00a0 | \u00a0 | (25,986 | ) |
| Non-operating income (expense), net | \u00a0 | \u00a0 | 8,092 | \u00a0 | \u00a0 | \u00a0 | (24,022 | ) | \u00a0 | \u00a0 | (386 | ) | \u00a0 | \u00a0 | (44,631 | ) |
| Loss before income taxes | \u00a0 | \u00a0 | (23,259 | ) | \u00a0 | \u00a0 | (792,331 | ) | \u00a0 | \u00a0 | (63,994 | ) | \u00a0 | \u00a0 | (909,336 | ) |
| Income tax expense (recovery), net | \u00a0 | \u00a0 | 1,974 | \u00a0 | \u00a0 | \u00a0 | 1,203 | \u00a0 | \u00a0 | \u00a0 | 3,235 | \u00a0 | \u00a0 | \u00a0 | 4,125 | \u00a0 |
| Net loss | \u00a0 | $ | (25,233 | ) | \u00a0 | $ | (793,534 | ) | \u00a0 | $ | (67,229 | ) | \u00a0 | $ | (913,461 | ) |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 5,979 | \u00a0 | \u00a0 | $ | 5,839 | \u00a0 | \u00a0 | $ | 18,359 | \u00a0 | \u00a0 | $ | 18,773 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 52,570 | \u00a0 | \u00a0 | \u00a0 | 49,315 | \u00a0 | \u00a0 | \u00a0 | 179,085 | \u00a0 | \u00a0 | \u00a0 | 165,627 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 1,165 | \u00a0 | \u00a0 | \u00a0 | 3,893 | \u00a0 | \u00a0 | \u00a0 | 6,666 | \u00a0 | \u00a0 | \u00a0 | 15,993 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 24,121 | \u00a0 | \u00a0 | \u00a0 | 13,935 | \u00a0 | \u00a0 | \u00a0 | 57,668 | \u00a0 | \u00a0 | \u00a0 | 40,991 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (19,007 | ) | \u00a0 | \u00a0 | (18,708 | ) | \u00a0 | \u00a0 | (64,907 | ) | \u00a0 | \u00a0 | (60,209 | ) |
| Total | \u00a0 | $ | 64,828 | \u00a0 | \u00a0 | $ | 54,274 | \u00a0 | \u00a0 | $ | 196,871 | \u00a0 | \u00a0 | $ | 181,175 | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the nine months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | February 28, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||||
| USA | \u00a0 | $ | 51,683 | \u00a0 | \u00a0 | $ | 64,420 | \u00a0 | \u00a0 | $ | 173,482 | \u00a0 | \u00a0 | $ | 200,053 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 48,221 | \u00a0 | \u00a0 | \u00a0 | 45,930 | \u00a0 | \u00a0 | \u00a0 | 160,561 | \u00a0 | \u00a0 | \u00a0 | 158,555 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 104,955 | \u00a0 | \u00a0 | \u00a0 | 72,386 | \u00a0 | \u00a0 | \u00a0 | 293,363 | \u00a0 | \u00a0 | \u00a0 | 229,312 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 1,873 | \u00a0 | \u00a0 | \u00a0 | 3,044 | \u00a0 | \u00a0 | \u00a0 | 6,334 | \u00a0 | \u00a0 | \u00a0 | 8,854 | \u00a0 |
| Total | \u00a0 | $ | 206,732 | \u00a0 | \u00a0 | $ | 185,780 | \u00a0 | \u00a0 | $ | 633,740 | \u00a0 | \u00a0 | $ | 596,774 | \u00a0 |
| \u00a0 | \u00a0 | February 28, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2025 | \u00a0 | ||
| USA | \u00a0 | $ | 188,500 | \u00a0 | \u00a0 | $ | 200,003 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 251,645 | \u00a0 | \u00a0 | \u00a0 | 267,458 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 98,571 | \u00a0 | \u00a0 | \u00a0 | 97,371 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 4,292 | \u00a0 | \u00a0 | \u00a0 | 3,601 | \u00a0 |
| Total | \u00a0 | $ | 543,008 | \u00a0 | \u00a0 | $ | 568,433 | \u00a0 |
Note 26. Subsequent Events
\n\u00a0
\nOn March 2, 2026, Tilray Brands UK Ltd (\u201cTilray UK\u201d), a wholly owned subsidiary of the Company, entered into a Business and Asset Sale Agreement (the \u201cBrewDog BASA\u201d). Under the BrewDog BASA, Tilray UK acquired certain business operations and assets of BrewDog plc and certain of its subsidiary undertakings (collectively, the \u201cBrewDog Group\u201d) through a pre-packaged administration process in Scotland under the Insolvency Act 1986, with the intent for Tilray UK to carry on the acquired business operations and assets as a going concern.\u00a0. The assets acquired included the brewery located in Ellon, Aberdeenshire, Scotland (the \u201cUK Brewery\u201d), the on-line business, the retail business, 11 of the BrewDog strategic brewpubs in Scotland, England and Ireland and all the intellectual property rights relating to the BrewDog brand, including sub-brands such as Punk IPA, Hazy Jane, Wingman, Elvis Juice and Dead Pony Club. The purchase price was \u00a0(approximately $44,100).\u00a0
\n\u00a0
\nOn March 9, 2026, the Company acquired BrewDog Brewing Australia Pty Ltd., which included BrewDog\u2019s Australian brewery, along with two hospitality venues in Australia for a nominal consideration.\u00a0
\n\u00a0
\nOn March 16, 2026, Tilray BrewDog U.S., Inc., a wholly-owned subsidiary of the Company, entered into an asset purchase agreement to acquire certain strategic BrewDog assets in the U.S., including a brewery, pub, and hotel in Columbus, Ohio, as well as pubs located in New Albany, Ohio, Cleveland, Ohio, and Las Vegas, Nevada. The purchase price for BrewDog\u2019s U.S. assets is equal to $9,296.
\n\u00a0
\nOn March 23, 2026, the Company acquired 5\u00a0additional BrewDog\u00a0brewpubs in Scotland and\u00a0England for a purchase price of (approximately $466).
\n "}]},{"name":"rpt:f-1839","factDimensions":{"xbrl:concept":"us-gaap:AssetAcquisitionConsiderationTransferred","xbrl:period":"2026-03-02T00:00:00/2026-03-03T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"tlry:BrewdogPlcMember","srt:StatementGeographicalAxis":"country:GB","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"44100000","decimals":-5}]},{"name":"rpt:f-1840","factDimensions":{"xbrl:concept":"us-gaap:AssetAcquisitionConsiderationTransferred","xbrl:period":"2026-03-16T00:00:00/2026-03-17T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"tlry:BrewdogPlcMember","srt:StatementGeographicalAxis":"country:US","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"9296000","decimals":-3}]},{"name":"rpt:f-1841","factDimensions":{"xbrl:concept":"us-gaap:AssetAcquisitionConsiderationTransferred","xbrl:period":"2026-03-23T00:00:00/2026-03-24T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AssetAcquisitionAxis":"tlry:BrewdogPlcMember","srt:StatementGeographicalAxis":"country:GB","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"466000","decimals":-3}]},{"name":"rpt:f-1842","factDimensions":{"xbrl:concept":"ecd:MtrlTermsOfTrdArrTextBlock","xbrl:period":"2025-06-01T00:00:00/2026-03-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n \n\u00a0
\napplicable.
\n "}]}]}}